

December 2019

Personal Data

Name: Ioannis Souglakos (John Souglakos)

Current position:

- Associata Profesor of Medical Oncology, Medical School, University of Crete

MD: Faculty of Medicine, University of Crete July 1990

PhD: Faculty of Medicine, University of Crete January 2001

Medical License: **1850/12/09/90 Department of Public Health, Prefecture of Peraius**

License in Medical Oncology: 91121/05/02-02-06 Department of Public Health, Prefecture of Heraklion

ADDRESS:

Business Address

Laboratory of Cancer Biology

Medical School

University of Crete

Corridor 9B

Phone +302810-394573

Fax +302810-394582

University Hospital of Heraklion
Voutes and Stavrakia PO Box 1352,
71110 Heraklion, Crete
Phone +302810-392784
Fax +302810-392857

Home Address

Pausaniou 3 Str,

Heraklion 71305, Crete, Greece

Tel: +302810 251835

Mobile: +306945261025

Fax +302810 392857

email: johnsougl@gmail.com, souglak@uoc.gr

Date of Birth: July 25 1965

Languages: English (C1), Danish (B2), Spanish (fluent), Catalan (reading and understanding)

EDUCATION POST-GRADUATED STUDIES DIPLOMAS

Degree in Medicine July 1990 University of Crete (8.36, 1st of the class)

PhD January 2001 University of Crete

Board in Medical Oncology 2006

My studies in medicine were realised in the Medical Faculty of the University of Crete. I began my doctoral thesis under the supervision of Prof. O. Manousos and after his retirement under the supervision of Prof. I. Blachonikolis. After my first two years of specialisation in Internal Medicine, I served as a supernumerary Doctor of the University Hospital of Heraklion. As such, I was placed in the Department of Medical Oncology of the hospital where the conduction of the cooperative international studies of the department was assigned to me. This was my first contact with the object of clinical research. Since then this particular object constitutes one from my inquiring interests and I have dealt with all spectrum of clinical investigation (planning, concretisation, control, analysis and report). I continued working as MD of clinical studies in Medical Oncology after the expiry of my appointment with the hospital and until 2001, with a short interval. From 2001, I began my specialization in Medical Oncology, first as a resident in Hematology for 6 months and afterwards as a resident in the Medical Oncology. After examination, in December 2005 I received the title of the Medical Oncology Speciality.. During my specialization, I enjoyed a scholarship from the Hellenic Society of Medical Oncology (HESMO) and worked in the Laboratory of Germans Trias i Pujol, Universitat Autonomus de Barcelona (5/2003-12/2003) under the supervision of Professor R Rosell. Furthermore, during my specialization, I was accepted and I followed the educational program of the Masterclass in Oncology of the European School of Oncology (in year 2004) and the AACR course “Molecular Biology in Clinical Oncology” (in July 2006). I was elected as lecturer of Medical Oncology in the Faculty of Medicine, University of Crete in November 2006. I took a sabbatical year (from November 2007-November 2008) at the Dana Farber Cancer Institute (Harvard Medical School) and 21 months in the Danish Health system (01/03/14-30/11/2015 Onkologisk Afdeling, Hospitalenhed Vest, Herning, Danmark)

I participate in a wide variety of events (congresses, seminars, workshops etc) as trainee as well as instructor.

1984-1990	Medical School, University of Crete, Heraklion
1990-1992	Military Service
1992-1993	Medical Doctor in Rural Service
1994-2000	PhD: Activation of IGF pathway in Colorectal Cancer
2/1995-10/98:	Intern (Internal Medicine) Univ Hosp of Heraklion
5/2001-11/2001	Intern (Haematology) Venizelion General Hosp of Heraklion
23/10/2002-22/10/2005	Intern (Med Oncology) Univ Hosp of Heraklion
01/5/2003-22/12/2003	Training in pharmacogenomics in laboratory of molecular biology in University Hospital of “Germans Trias i Pujol”

	Badalona, Barcelona, Spain (Head of the Department: Dr R Rosell)
10/2003-12/2005	Research Fellow in laboratory of tumor biology, University of Crete, Heraklion, Crete, Greece
12/2005	Title of specialization in Medical Oncology
14/11/07-6/11/08	Sabbatical in DANA FARBER CANCER INSTITUTE, Harvard Medical School, Boston (PI Ramesh Shivdasani).
01/03/14-30/11/2015 Danmark	Onkologisk Afdeling, Hospitalenhed Vest, Herning,
5/2007-to day	Faculty member, Medical School, University of Crete

APPOINTMENTS

08/09/2014- 12/2015	Hospitalsundhed Vest, Onkologisk Afdeling, Herning, Danmark
20/05/2007- 10/10/2018	Assistant Professor of Medical Oncology, School of Medicine, University of Crete
10/10/2018-now	Associate Professor of Medical Oncology, School of Medicine, University of Crete
01/2006-11/2007	Director of Clinical Trials Office, University Hospital of Heraklion, Crete, Greece
12/2005- now	Principal Investigator in the Laboratory of Cancer Biology, Coordinator of the Genomic-Biomarkers Projects
11/2014-2018	President of the scientific committee of the Hellenic Oncology Research Group (HORG)
2/2013-now	President of the GastroIntestinal Cancer- Study Group (GIC-SG)

TEACHING EXPERIENCE

a. Undergraduate studies:

1. Attendance in the teaching of Internal Medicine courses to the students of the Medical Faculty during the years 2002-2003 and 2006-2012.
2. Attendance in the teaching of the course “Therapeutic strategy of neoplastic disease” to the students of the Medical Faculty on years 2000,2001,2002,2003 and 2006-2011.
3. Attendance in the teaching of the course “Principals and mechanism of oncogenesis” to the students of the Medical Faculty on years 1999, 2000, 2001 and 2005-2012.
4. Attendance in the teaching of “Summer School of Oncology for Medical Students” from 2009 to2012.

b. Postgraduate education:

1. Attendance in the teaching of course “Import in the Clinical Methodology” in the frames of the postgraduate program “Cellular and Genetic Explanation, Diagnostics and Therapeutics of Human Disease” of the Medical School, University of Crete (years 2004-2006).
2. Attendance in the teaching of post graduate courses of Surgical Pathology of the abdomen (Dep. of Surgery University Hospital of Heraklion 2006-2011).
3. Attendance in the teaching of post graduate courses of “Molecular and Applied Physiology” of the Medical School, University of Athens (year 2011).
4. Member of Scientific Committee of 11th World Conference on Lung Cancer 2005.
5. Supervisor of 4 pre-doctoral students in the laboratory.
6. Mentor of 5 post-doctoral fellow in the laboratory.
7. Member of Scientific Committee of Annual meeting in Oncology in Heraklion from 2005 to 2011.
8. Organisation and Concretisation of clinical seminar for “Clinical Trials in the Oncology: Applications and Evaluation” in the frames of 7th Congress of Clinical Oncology 1999.
9. Organisation of the 1st Workshop of Clinical Trials on 16-18 January 2007).
10. Organization of the annual students’ meetings for training in Oncology (2006-2012).

c. Invited speaker:

Invitation for participation in more than 80 round tables and more than 35 invited lectures

Clinical Experience

1990- 1992	Military Service as Medical Doctor
1992-1993	Medical Doctor in Rural Service
2/1995-10/98:	Intern (Internal Medicine) Univ Hosp of Heraklion
5/2001-11/2001	Intern (Haematology) Venizelion General Hosp of Heraklion
23/10/2002-22/10/2005	Intern (Med Oncology) Univ Hosp of Heraklion
20/05/2007-since now	Department of Medical Oncology, School of Medicine, University of Crete

Laboratory Experience

- a) 1999 Laboratory of epidemiology, Medical School, University of Athens: Quantification of IGF-I level in the serum of patients with colorectal cancer (Mentor: Ass Professor A Tzonou)
- b) **2003-since today:** Laboratory of Cancer Biology, School of Medicine, University of Crete. Director of the pharmacogenomic project (gene expression profiles, SNPs analysis, and mutations analysis). Establishment of markers for evaluation of micrometastatic disease in patients with colorectal cancer.
- c) **5/2003-12/2003:**Laboratory of pharmacogenomics Germans Trais i Pujol Universitat Autonomus de Barcelona, Badalona, Barcelona, Spain (mentor Professor R Rosell)
- d) **14/11/2007 – 11/11/2008:** Laboratory of molecular biology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School (mentor Ramesh Shivdasani).
- e) **11/2008** Principal Investigator of the pharmacogenomic and biomarkers group in the laboratory of Tumor Cell Biology, Faculty of Medicine, University of Crete

Research Activities

1. Clinical Research

- * Coordinator for the group of molecular targeted therapies and Colorectal Cancer studies of the Hellenic Oncology Research Group.
- * International collaborations with EORTC –GI group, IDEA trial and ETOP.

ISTs

- i) MERCK KGaA: A Triplet Combination With Irinotecan (Cpt-11) Plus Oxaliplatin (L-Ohp), Continuous Infusion 5-Fluorouracil (5-Fu) And Leucovorin (Lv) (Folfoxiri) Plus Cetuximab (C-225) As First Line Treatment In Metastatic Colorectal Cancer (Mcc): A Multicenter Pilot Phase Ii Trial Trial Code 20060411 (Principal Investigator J Souglakos) (2006)
- ii) MERCK KGaA: A Phase Ii Trial Of Preoperative Radiotherapy In Combination With Ufox (Uft, Folinic Acid, Oxaliplatin) And Cetuximab For Patients With Stage Ii And Iii Operable Rectal Cancer (Principal Investigator J Souglakos) 2007
- iii) AMGEN A pilot study to evaluate the efficacy of panitumumab maintenance in eliminating circulating tumour cells (CTCs) in the blood of patients with KRAS-WT colorectal cancer with an initial response or stable disease after front line chemotherapy. **EudraCT Number:200912157-38**
- iv) Cell Gene: Nab-Paclitaxel as salvage treatment for patients with advanced metastatic cancer of the stomach or the Gastroesophageal junction.
- v) Sanofi-Aventis: Investigation of Cabazitaxel efficacy in lung cancer cell lines resistant to docetaxel and paclitaxel due to overexpression of *TXR1*.
- vi) Detection of prognostic and predictive biomarkers in patients with operable (stage II-III) colorectal cancer **ELKE**, Research Committee, University of Crete No: 3701 (2012)

Participation in international clinical trials:(V303, V212, TAX-V307, CPTV307, V316, V305, V322, V326, SCOTROC, 157-002, FUMB02 ,I 352, I 328 ,GCS 102, MOSAIC ,X*ACT ,BAY-012, CRYSTAL, FUTURE).

Participation in Clinical Research Programs

Funding member of Hellenic Oncology Research Group (HORG).

Coordinator of the group for treatment of colorectal cancer HORG

Member of

- European Thoracic Oncology Platform (ETOP)- member or the steering committee for translational research of the group
- EORTC-Gastrointestinal Group
- ACCENT consortium for the management and treatment of operable colorectal cancer

2. Laboratory Research

- a. Systematic genomic analysis of colorectal cancer.
- b. Clinical investigations for the management and treatment of colorectal cancer
- c. Identification of prognostic and predictive molecular markers for the outcome of patients with NSCLC.
- d. Mutation analysis of EGFR and related genes in the pathway of the ERB receptors family and correlation with response to targeted therapies.
- e. Mutation analysis of genes frequently mutated in colorectal cancer (Kras, BRAF, PIK3CA etc) and the application of this analysis in treatment decisions.
- f. Prognostic and predictive molecular markers for the outcome of patients with operable gastric cancer.
- g. Identification of markers for the evaluation of micrometastatic disease for patients with colorectal cancer and NSCLC.

Awards and Distinctions

2003 Scholarship from the Hellenic Society of Medical Oncology (HeSMO)

2007 Scholarship from the Hellenic Society of Medical Oncology (HeSMO)

Participation as national representative in the Expert meeting for the ESMO Guidelines for the diagnosis, management and treatment of colorectal cancer in 2010

1st Price Annual meeting of the Hellenic Society of Pathology 2005

1st Price Annual meeting of the Hellenic Society of Medical Oncology 2010

3rd Price Annual meeting of the Hellenic Society of Medical Oncology 2010

1st Price Annual meeting of the Hellenic Society of Medical Oncology 2011

Membership in Scientific Societies

* EORTC (European Oncology for Research and Treatment of Cancer) GI group

- * European Thoracic Oncology Platform (ETOP)

- * American Society of Clinical Oncology (ASCO)

- * American Association for Cancer Research (AACR)

- * International Society of Geriatric Oncology (SIOG)

- * Member of the steering committee of IDEA trial

- * Member of the ARCAD group

- * Hellenic Society of Medical Oncology (HeSMO)
- * Leader of the Gastro-intestinal Cancer Study Group
- * President of the scientific committee of the Hellenic Oncology Research Group (HORG)

PUBLICATIONS

Publications in SCI Journals

Published manuscripts 136

Impact Factor

Mean: 6.659

Citations:

Google Scholar: 7733 h-factor 44, i-10 95;
since 2014: 3990, h-factor 30, i-10 63

Scopus 5361 (4811), h factor: 37 (36)

ISIS Web of Science: 4858 (4724), h factor: 35, average: 22.6

1. Georgoulas V, Kourousis C, Androulakis N, Kakolyris S, Papadakis E, Bouros D, Apostolopoulou F, Georgopoulou T, Agelidou M, **Souglakos J**, Halkiadakis G, Hatzidaki D. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer. *Semin Oncol*. 1997; 24:S14-9-S14-14.
2. Kakolyris S, Samonis G, Koukourakis M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, **Souglakos I**, Agelaki S, Toloudis P, Georgoulas V. Treatment of non-small-cell lung cancer with prolonged oral etoposide. *Am J Clin Oncol*. 1998 Oct; 21(5):505-8.
3. Georgoulas V, Androulakis N, Bouros D, Kouroussis C, Chatzakis K, Papadakis M, Apostolopoulou F, Georgopoulou T, Kotsakis T, **Souklakos J**, Hatzidaki D, Vlachonikolis J, Panagos G. Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer. *Lung Cancer*. 1998; 21(3):213-20.
4. Androulakis N, Kouroussis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyanni A, Georgopoulou T, Dimopoulou I, **Souglakos J**, Kotsakis A, Vardakis N, Hatzidaki D, Georgoulas V. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. *Ann Oncol*. 1998 Oct; 9(10):1127-30.
5. Kourousis C, Androulakis N, Kakolyris S, **Souglakos J**, Maltezas G, Metaxaris G, Chalkiadakis G, Samonis G, Vlachonikolis J, Georgoulas V. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. *Cancer*. 1998 Nov 15; 83(10):2083-90.
6. Sara E, Kotsakis A, **Souklakos J**, Kourousis C, Kakolyris S, Mavromanolakis E, Vlachonicolis J, Georgoulas V. Post-chemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4+ cell proliferation. *Anticancer Res*. 1999; 19(1A):471-6.

7. Kouroussis C, Androulakis N, Kakolyris S, **Souglakos J**, Kotsakis T, Mavroudis D, Katsogridakis K, Vardakis N, Hatzidaki D, Samonis G, Vlachonikolis J, Georgoulis V. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. *J Clin Oncol*. 1999 Mar; 17(3):862-9.
8. Mannousos O, **Souglakos J**, Besetting C, Toni A, Hatzidaki V, Trichopoulos D, Adami HO, Mantzoros C. IGF-I and IGF-II in relation to colorectal cancer. *Int J Cancer*. 1999 Sep 24; 83(1):15-7.
9. Kouroussis C, Georgoulis V, **Souglakos J**, Simvoulakis E, Karabekios S, Samonis G. Spontaneous spondylodiscitis caused by *Klebsiella pneumoniae*. *Infection*. 1999 Nov-Dec; 27(6):368-9.
10. Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki S, **Souglakos J**, Mavromanomakis E, Vlachonikolis J, Georgoulis V. Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis. *Cancer*. 2000 Sep 15; 89(6):1380-6.
11. Mavroudis D, Kourousis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, **Souglakos J**, Vardakis N, Samonis G, Georgoulis V. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. *Semin Oncol*. 2000; 27(1 Suppl 2):25-30.
12. Kouroussis C, Samonis G, Androulakis N, **Souglakos J**, Voloudaki A, Demopoulos MA, Kotsakis T, Kakolyris S, Kalbakis K, Georgoulis V. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. *Am J Clin Oncol*. 2000; 23(3):309-13.
13. Kakolyris S, Kouroussis C, Kalbakis K, Mavroudis D, **Souglakos J**, N Vardakis, Kermis S, Georgoulis V. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin. *Ann Oncol*. 2000 Jun; 11(6):757-60.
14. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, **Souglakos J**, Sarra E, Vardakis N, Hatzidaki D, Sarmonis G, Georgoulis V. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. *Am J Clin Oncol*. 2000 Aug; 23(4):341-4.
15. Kakolyris S, **Souglakos J**, Agelaki S, Kourousis CH, Mavroudis D, Sarra E, Malliotakis P, Georgoulis V. A dose-escalation study of irinotecan (CPT-11) in combination with Cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy. *Lung Cancer*. 2000 Dec; 30(3):193-8.

16. Kouroussis C, Agelaki S, Mavroudis D, **Souglakos J**, Kakolyris S, Kalbakis K, Vardakis N, Reppa D, Hatzidaki D, Samonis G, Georgoulas V. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2000; 46(6):488-92.
17. Kakolyris SA, Kaklamanis LG, Koukourakis MJ, Giatromanolaki A, Rousomoustakaki M, **Souglakos JC**, Reppa DK, Georgoulas VA, Gatter KC, Harris AL. Angiogenesis and p53 expression in the colorectal adenoma-carcinoma sequence. *Oncol Res.* 2000; 12(4):203-8.
18. Kakolyris S, Mavroudis D, Tsavaris N, **Souglakos J**, Tsiafaki P, Kalbakis K, Agelaki S, Androulakis N, Georgoulas V. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. *Ann Oncol.* 2001 Feb; 12(2):193-7.
19. Kakolyris S, **Souglakos J**, Kouroussis C, Androulakis N, Mavroudis D, Kalbakis K, Kotsakis A, Vardakis N, Koukourakis M, Romanos J, Georgoulas V. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. *Oncology.* 2001; 60(3):207-13.
20. Agelaki S, Bania H, Kouroussis C, Blazoyiannakis G, **Souglakos J**, Tsiafaki X, Harpidou A, Kalbakis K, Rapti A, Androulakis N, Sarra E, Georgoulas V, Papadakis E. Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials. *Oncology.* 2001; 60(3):235-41.
21. Kouroussis C, **Souglakos J**, Kakolyris S, Mavroudis D, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulas V. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. *Oncology.* 2001; 61(1):36-41.
22. Kouroussis C, Kakolyris S, Mavroudis D, Androulakis N, Kalbakis K, Agelaki S, Sarra E, **Souglakos J**, Christodoulakis M, Samonis G, Georgoulas V. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. *Am J Clin Oncol.* 2001 Aug; 24(4):404-7.
23. Samonis G, Anatoliotaki M, Apostolakou H, **Souglakos J**, Georgoulas V. Fatal septicemia and meningitis due to *Morganella morganii* in a patient with Hodgkin's disease. *Scand J Infect Dis.* 2001; 33(7):553-5.
24. Kalbakis K, Kouroussis C, Kakolyris S, Mavroudis D, **Souglakos J**, Agelaki S, Vamvakas L, Christodoulakis M, Stylianos K, Georgoulas V. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes. *Br J Cancer.* 2001 Sep 14; 85(6):798-802.

25. Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, **Souglakos J**, Kakolyris S, Georgoulas V. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicenter phase II study. *Eur J Cancer*. 2001 Oct; 37(15):1833-8.
26. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, **Souglakos J**, Sivridis E, Georgoulas V, Gatter KC, Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. *Clin Cancer Res*. 2001 Oct; 7(10):3087-91.
27. Kakolyris S, Kouroussis C, **Souglakos J**, Mavroudis D, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulas V. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. *Oncology*. 2001; 61(4):265-70.
28. Kakolyris S, Kouroussis C, **Souglakos J**, Agelaki S, Kalbakis K, Vardakis N, Vamvakas L, Georgoulas V. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2001 Dec; 34 Suppl 4:S71-6.
29. Agelaki S, Bania H, Kouroussis C, Blazoyiannakis G, **Souglakos J**, Tsiafaki X, Kalbakis K, Rapti A, Androulakis N, Georgoulas V, Papadakis E. Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study. *Lung Cancer*. 2001 Dec; 34 Suppl 4:S77-80.
30. Kakolyris S, **Souglakos J**, Kouroussis C, Koukoutakis M, Kalbakis K, Mavroudis D, N Vardakis, Georgoulas V: A dose-escalation of Irinotecan (CPT-11) with Gemcitabine in patients with advanced Non-small Cell Lung Cancer previously treated with a cis-platin-based front line chemotherapy. *Anticancer Res* 2002; 22:1891-1896.
31. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, **Souglakos J**, Georgoulas V. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. *Am J Clin Oncol*. 2002 Feb; 25(1):65-70.
32. Kosmas C, Agelaki S, Giannakakis T, Mavroudis D, Kouroussis Ch, Kalbakis K, Papadouris S, **Souglakos J**, Malamos N, Georgoulas V. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. *Oncology*. 2002; 62(2):103-9.
33. **J Souglakos**, D Mavroudis, S Kakolyris, Ch Kouroussis, N Vardakis, N Androulakis, S Agelaki, K Kalbakis, D Tsetis, N Athanasiadis, G Samonis, V Georgoulas. A triplet combination with irinotecan (CPT-11) plus oxaliplatin (l-OHP) plus continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) as first line treatment in metastatic

- colorectal cancer (mcc): a multicenter phase II trial. *J Clin Oncol.* 2002; 20(11):2661-2667
34. Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, **Souglakos J**, Samonis G, Georgoulas V. Phase I study of Paclitaxel (taxol) and pegylated liposomal Doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors. *Oncology* 2002;62(3):216-22
 35. **J Souglakos**, A. Kotsakis, Ch. Kouroussis, S. Kakolyris, D. Mavroudis, K. Kalbakis, S. Agelaki, J. Vlachonikolis, V. Georgoulas, G. Samonis. Non neutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. *Cancer* 2002 Sep 15; 95(6):1326-33.
 36. Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, **Souglakos J**, Magkanas E, Samonis G, Georgoulas V; Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. *Lung Cancer* 2002 Oct; 38(1):59-63.
 37. Androulakis N, Kouroussis C, Kakolyris S, Mavroudis D, Kalbakis K, Agelaki S, **Souglakos J**, Vardakis N, Samonis G, Georgoulas V. A dose-finding study of the weekly administration of paclitaxel and caelyx in patients with advanced solid tumors. *Eur J Cancer* 2002; 38(15):1992-7.
 38. Kouroussis C, **Souglakos J**, Kakolyris S, Mavroudis D, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulas V. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as salvage treatment in patients with advanced colorectal cancer: a phase II study. *Am J Clin Oncol* 2002; 25(6):627-31.
 39. Giannakakis Th, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, **Souglakos J**, Agelaki S, Vardakis N, Georgoulas V. A multicenter phase II study of Docetaxel and Carboplatin combination as front-line treatment in advanced Non-small Cell Lung Cancer. *Anticancer Research* 2002 Nov-Dec; 22(6B):3743-8
 40. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, **Souglakos J**, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulas V. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. *Ann Oncol*, 2003;14(2):304-12.
 41. C Kourousis, S Agelaki, D Mavroudis, S Kakolyris, N Androulakis, K Kalbakis, **J Souglakos**, K Mallas, V Bozionelou, A Pallis, H Adamtziki, V Georgoulas. A dose escalation study of Docetaxel and Oxaliplatin Combination in patients with metastatic breast and Non-Small-Cell lung Cancer. *Anticancer Res*, 2003, 23: 785-792.

42. A Pallis, D Mavroudis, I Vlachonikolis, N Androulakis, V Bozionelou, **J Souglakos**, V Georgoulas. ZD 1839 as salvage treatment of advanced NSCLC: A phase II study. *Lung Cancer* 2003, 40: 301-307.
43. **J Souglakos**, N Androulakis, D Mavroudis, C Kourousis, S Kakolyris, N Vardakis, K Kalbakis, A Pallis, A Ardavanis, C Varveris, V Georgoulas. Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. *Int J Radiation Oncology Biol Phys* 2003, 56: 1285-87.
44. C Kourousis, D Mavroudis, S Kakolyris, A Voloudaki, K Kalbakis, **J Souglakos**, S Agelaki, K Malas, V Bozionelou, V Georgoulas. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: Results of a dose-finding study. *Lung Cancer*. 2004 Jun; 44(3):363-8.
45. **J. Souglakos**, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, A. Kotsakis, V. Georgoulas. Combination Of Irinotecan (Cpt-11) Plus Oxaliplatin (L-Ohp) As First Line Treatment In Locally Advanced Or Metastatic Gastric Cancer: A Multicenter Phase II Trial. *Ann Oncol.*2004 Aug; 15(8):1204-9.
46. S Kakolyris, **J Souglakos**, C Kourousis, N Androulakis, G Samonis, N Vardakis, K Amarantidis, S Agelaki, D Mavroudis, N Xenidis, V Georgoulas. A dose-escalating study of oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. *Oncology*. 2004; 66(4):253-9.
47. Taron M, Rosell R, Felip E, Mendez P, **Souglakos J**, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. *Hum Mol Genet*. 2004 Oct 15; 13(20):2443-9.
48. C. Kourousis, K. Kalbakis, N. Androulakis, S. Agelaki, L. Vamvakas, K. Malas, **J. Souglakos**, N. Vardakis, V. Georgoulas, et al. A dose escalating study of Leucovorin (LV) and continuous infusion 5-Fluorouracil in combination with Cyclophosphamide and Vinorelbine in pretreated patients with metastatic breast cancer. *Anticancer Research* 2004 24: 4217-4222.
49. **J Souglakos**, S Kakolyris, N Vardakis, D Mavroudis, L Vamvakas MD , C Kourousis, S Agelaki, K Kalbakis, Z Saridaki, V Georgoulas: A Dose Escalating Study Of Oxaliplatin (L-Ohp) And High Dose Weekly Leucovorin (Lv) And 5-Fluorouracil (5fu) In Patients With Advanced Solid Tumors. *Cancer Investigation* 2005; 23:505-510.
50. **J. Souglakos**, A. Pallis, S. Kakolyris, D. Mavroudis, N. Androulakis, Ch. Kouroussis, S. Agelaki, N. Xenidis, G. Milaki, V. Georgoulas. Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. *Oncology*. 2005; 69(5):384-90.

51. **J. Souglakos**, N. Androulakis, K. Syrigos, A. Polyzos, N. Ziras, A. Athanasiadis, S. Kakolyris, S. Tsousis, Ch. Kouroussis, L. Vamvakas, A. Kalykaki, G. Samonis, D. Mavroudis, V. Georgoulis. FOLFOXIRI (folinicacid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinicacid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre and omitted phase III trial from the Hellenic Oncology Research Group (HORG). *BrJCancer*. 94: 798-805; 2006.
52. **John Souglakos**, Lambros Vamvakas, Stella Apostolaki, Maria Perraki, Zacharenia Saridaki, Irene Kazakou, Athanasios Pallis, Charalambos Kouroussis, Nikolaos Androulakis, Kostas Kalbakis, Georgia Millaki, Dimitris Mavroudis, Vassilis Georgoulis. Central nervous system (CNS) involvement in patients with breast cancer is associated with the presence of circulating occult tumor cells and the HER2/neu status *Breast Ca Res Treat* 8; 4: 1-8 2006.
53. A.G. Pallis, Ch. Christofillakis, E. Tselepatiotis, S. Agelaki, L. Vamvakas, **J. Souglakos**, N. Vardakis, A. Kalykaki, A. Kotsakis, A. Argiraki, D. Mavroudis, V. Georgoulis Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial. *Lung Cancer* 55: 101-107, 2007.
54. **J. Souglakos**, A Kalykaki, L Vamvakas, N Androulakis, K Kalbakis, S Agelaki, N Vardakis, M Tzardi, A P Kotsakis, J Gioulbasanis, D Tsetis, G Sfakiotaki, D Chatzidaki, D Mavroudis, V Georgoulis. Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) plus Cetuximab in Patients With Metastatic Colorectal Cancer Who Progressed After Oxaliplatin-based Chemotherapy. *Ann Oncol* 18; 2: 305-310 2007.
55. **J. Souglakos**: Genetic Alterations in Sporadic and Hereditary Colorectal Cancer: Implementations for Screening and Follow Up. *Dig Diseases* 25; 1: 9-19, 2007.
56. **J. Souglakos**, N. Vardakis, N. Androulakis, S. Kakolyris, Ch. Kouroussis, D. Mavroudis, A. Pallis, S. Agelaki, K. Kalbakis, V. Georgoulis: Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. *J of BUON*; 10: 47-52, 2005.
57. Anastassios V. Koutsopoulos, Dimitris Mavroudis, Konstantina I. Dambaki, **John Souglakos**, Eleni G. Tzortzaki, John Drositis, George S. Delides, Vassilis Georgoulis and Efstathios N. Stathopoulos. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in Non-Small-Cell Lung Carcinomas: correlation with clinical outcome. *Lung Cancer* 55: 101-7; 2007.
58. Christos Emmanouilides, Georgia Sfakiotaki, Nikolaos Androulakis, Kostas Kalbakis, Charalambos Christophylakis, Antonia Kalykaki, Lambros Vamvakas, Athanasios Kotsakis, Sofia Agelaki, Eleni Diamandidou, Nikolaos Touroutoglou, Adam Chatzidakis, Vassilis Georgoulis, Dimitris Mavroudis, **John Souglakos**:

- Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study *BMC-Cancer* 7:91; 2007.
59. Ioannis Gioulbasanis, **John Souglakos**, Nikos Vardakis, Athanasios Kotsakis, Zenia Saridaki, Nikos Kentepozidis, Aris Polyzos, Stelios Giassas, Michael Ignatiadis, Vassiliki Bozionelou, Charalambos Christophilakis, Vassilis Georgoulis. Dose Escalating Clinical Study Of High Dose Infusional 5-Fluorouracil And Leukovorin (Aio Regiment) Plus Alternate Weekly Administration Of Oxaliplatin And Irinotecan In Patients With Advanced Tumors Of The Gastro-Intestinal Tract. *Journal of BUON* 12:197-202; 2007.
 60. Pallis AG, Voutsina A, Kalikaki A, **Souglakos J**, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D, Georgoulis V. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. *Br J Cancer* 97:1560-6; 2007.
 61. **Souglakos J**, I Boukovinas, M Taron, P Mendez, D Mavroudis, M Tripaki, D Chatzidaki, A Koutsopoulos, E Stathopoulos, V Georgoulis, R Rosell. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. *Br J Cancer*: 98(10):1710-5; 2008.
 62. Stathopoulos GP, Androulakis N, **Souglakos J**, Stathopoulos J, Georgoulis V. Present treatment and future expectations in advanced pancreatic cancer. *Anticancer Res*: 28(2B):1303-8; 2008.
 63. Boukovinas I, **Souglakos J**, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, Mavroudis D, Georgoulis V. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study. *Lung Cancer*. 2009 Jan;63(1):77-82.
 64. Kakolyris S, **Souglakos J**, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulis V. Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every 2 Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Front-Line Therapy: A Multicenter Phase II Study. *Oncology*: 78(1-2): 31-36; 2008.
 65. Kalykaki A, Koutsopoulos A, Trypaki M, **Souglakos J**, Stathopoulos E, Georgoulis V, Mavroudis D, Voutsina A, Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. *Br J Cancer*: 2008;**99(6):923-9**.
 66. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulis V, Rosell R, **Souglakos J**. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and

- clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. *PLoS One*. 2008;3(11):e3695.
67. Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, Polyzos K, Tsigris C, Mantas D, Papachristodoulou A, Nikiteas N, Karavokyros JG, Felekouras E, Griniatsos J, Giannopoulos A, Kouraklis G. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. *Oncology*. 2009;76(1):36-41.
 68. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulas V, Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2009 Mar;10(2):118-23.
 69. Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A, Marselos M, Georgoulas V, Mavroudis D. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2009 Dec;65(1):121-8.
 70. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulas V, Souglakos J. Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. *Clin Cancer Res*. 2009 Jun 1;15(11):3827-33.
 71. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulas V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. *Br J Cancer*. 2009 Aug 4;101(3):465-72.
 72. Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, Polyzos A, Kouroussis C, Ziras N, Kalbakis K, Georgoulas V, Souglakos J. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). *Crit Rev Oncol Hematol*. 2010;76(1):61-70.
 73. Saridaki Z, Georgoulas V, Souglakos J. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. *World J Gastroenterol*. 2010 Mar 14;16(10):1177-87.
 74. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulas V, Souglakos J. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. *Br J Cancer*. 2010 Jun 8;102(12):1762-8.
 75. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-

line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. *Br J Cancer*. 2011 Jan 18;104(2):316-23.

76. Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulas V, Souglakos J. Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer (CRC). *Clin Cancer Res*. 2011, 17(1):165-73.
77. Z Saridaki, M Tzardi, Ch Papadaki, M Sfakianaki, F Pega, A Kalikaki, E Tsakalaki, M Trypaki, Ip Messaritakis, E Stathopoulos, D Mavroudis, V Georgoulas, John Souglakos. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in \geq 2nd line cetuximab-based therapy of colorectal cancer patients PLoS ONE 2011, e15980.
78. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varellaga Garcia M, Nakagawa K, Jänne PA. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab *Sci Transl Med*. 2011 Sep 7;3(99):99ra86.
79. Ioannidis G, Georgoulas V, Souglakos J. How close are we to customizing chemotherapy in early non-small cell lung cancer? *Ther Adv Med Oncol*. 2011 Jul;3(4):185-205.
80. Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis C, Kouroussis C, Vamvakas L, Georgoulas V, Polyzos A. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). *Br J Cancer*. 2012 Jan 12. doi: 10.1038/bjc.2011.594.
81. Papadaki Ch, Sfakianaki M, Ioannidis G, Lagoudaki L, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J. *ERCC1* and *BRAC1* mRNA expression in the primary tumour could predict the effectiveness of the 2nd-line cis-platin based chemotherapy in pretreated patients with metastatic Non Small Cell Lung Cancer. *J Thor Oncol* 2012 (in press).
82. H. J. Schmoll; E. Van Cutsem; A. Stein; V. Valentini; B. Glimelius; K. Haustermans; B. Nordlinger; C. J. van de Velde; J. Balmana; J. Regula; I. D. Nagtegaal; R. G. Beets-Tan; D. Arnold; F. Ciardiello; P. Hoff; D. Kerr; C.H. Kohne; R. Labianca; T. Price; W. Scheithauer; A. Sobrero; J. Tabernero; D. Aderka; S. Barroso; G. Bodoky; J. Y. Douillard; H. El Ghazaly; J. Gallardo; A. Garin; R. Glynn-Jones; K. Jordan; A. Meshcheryakov; D. Papamichail; P. Pfeiffer; L. Souglakos; S. Turhal; A. Cervantes ESMO Consensus Guidelines for management of patients with colon and

rectal cancer. A personalized approach to clinical decision making *Ann of Oncol* 2012 23: 2479-2516

83. Z. Saridaki, N. Androulakis, N. Vardakis, L. Vamvakas, E. Kabouraki, K. Kalbakis, D. Hatzidaki, A. Voutsina, D. Mavroudis, V. Georgoulas, **J. Souglakos**. A triplet combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), continuous infusion 5-Fluorouracil and Leucovorin (FOLFOXIRI) plus Cetuximab as first line treatment in KRAS wt, metastatic colorectal cancer (mCRC): a pilot phase II trial *Br J Ca* 2012 (in press).
84. Niki Karachaliou, Carlota Costa, Ana Gimenez-Capitan, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Clara Mayo, Bartomeu Massuti, Margarita Majem, Enric Carcereny, Teresa Moran, Jose Javier Sanchez, Santiago Viteri, Amaya Gasco, Luciano Wannesson, **John Souglakos**, Jose Jimeno, Rafael Rosell BRCA1, LMO4 and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations *J Thor Oncol* 2013 8(3):295-300.
85. Zacharenia Saridaki MD PhD, Georgia Lambrodinou MD, Stefanos Kachris MD, Paris Makrantonakis MD , Ioannis Boukovinas MD PhD, Aris Polyzos MD PhD, A Anagnostopoulos, Athanasios Athanasiadis MD PhD, Vassilis Georgoulas MD PhD, **John Souglakos** MD PhD Postoperative treatment with docetaxel, cis-platin and capecitabine (DCX) and chemo-radiotherapy (CRT) with capecitabine for resected gastric adenocarcinomas *Am J Med Oncol* 2013 published ahead of print, 3 April 2013
86. Karampeazis A, Voutsina A, **Souglakos J**, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulas V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study, *Cancer*. 2013 *Cancer*. 2013 Aug 1;119(15):2754-64. doi: 10.1002/cncr.28132.
87. André T, Iveson T, Labianca R, Meyerhardt JA, **Souglakos I**, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ; for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. *Curr Colorectal Cancer Rep*. 2013; 9:261-269. Review.
88. Matikas A, Vardakis N, **Souglakos J**, Georgoulas V. A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation. *BMJ Case Rep*. 2013 Sep 17;2013. doi:pii: bcr2013200502. 10.1136/bcr-2013-200502.
89. Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, Mavroudis D, Stathopoulos E, Georgoulas V, **Souglakos J**. Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. *PLoS One*. 2013 Sep 13;8(9): e74611. doi: 10.1371/journal.pone.0074611.

90. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulas V, Souglakos J BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013.
91. Saridaki Z, Souglakos J, Georgoulas V The prognostic and predictive significance of microsatellite instability (MSI) in stage II colon cancer World Journal of Gastroenterology 2014; Volume 20, Issue 22, 2014, Pages 6809-6814.
92. Vamvakas L. , Matikas, A. , Karampeazis, A. , Hatzidaki, D. , Kakolyris, S. , Christophylakis, C. , Boukovinas, I. , Polyzos, A. , Georgoulas, V. , Souglakos, J. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): A multicenter phase II study of the Hellenic Oncology Research Group (HORG) BMC Cancer Volume 14, Issue 1, 22 April 2014,
93. Katopodis, O. , Souglakos, J., Stathopoulos, E., Christopoulou, A., Kontopodis, E., Kotsakis, A., Kalbakis, K., Kentepozidis, N., Polyzos, A., Hatzidaki, D., Georgoulas, V. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology
94. Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, **Souglakos** J, Cappuzzo F, Cervantes A, Frattini M, Fountzilias G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut. 2014 Jul 10. pii: gutjnl-2014-307234. doi: 10.1136/gutjnl-2014-307234.
95. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C; Aide et Recherche en Cancérologie Digestive Foundation. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20;32(27):2975-84.
96. Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, Mavroudis D, Georgoulas V, Voutsina A. KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer PLoS One 2014 19;9(8):e104902. doi: 10.1371
97. Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulas V, Souglakos J. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. Br J Cancer. 2014 Oct 28;111(9):1757-64.
98. Shi Q, de Gramont A, Grothey A, Zalcborg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, **Souglakos** J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival

- versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. *J Clin Oncol*. 2015 Jan 1;33(1):22-8.
99. Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, **Souglakos J**, Mavroudis D, Georgoulas V. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. *Cancer Invest*. 2015 Feb 3. [Epub ahead of print]
 100. Matikas A, Asimakopoulou N, Georgoulas V, **Souglakos J**. The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. *Cancers (Basel)*. 2015 Mar 13;7(1):439-49.
 101. Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, **Souglakos J**, Georgoulas V, Iliopoulos D Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. *BMC Cancer*. 2015 Jul 24;15:542
 102. Souglakos J Customizing chemotherapy in Non-Small Cell Lung Cancer: The promise is still unmet. *Translational Lung Cancer Research*. *Transl Lung Cancer Res*. 2015;4(5):653-5. doi: 10.3978/j.issn.2218-6751.2015.03.10.
 103. Kountourakis P, **Souglakos J**, Gouvas N, Androulakis N, Athanasiadis A, Boukovinas I, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Makatsoris T, Papakostas P, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Xynos E, Ziras N, Papamichael D. Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. *Ann Gastroenterol*. 2016; 29(1):18-23.
 104. Xynos E, Gouvas N, Triantopoulou C, Tekkis P, Vini L, Tzardi M, Boukovinas I, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pentheroudakis G, Pilpilidis I, Sgouros J, Vassiliou V, Xynogalos S, Ziras N, Karachaliou N, Zoras O, Agalianos C, **Souglakos J** Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. *Ann Gastroenterol*. 2016; 29(1):3-17.
- Xynos E, Gouvas N, Triantopoulou C, Tekkis P, Vini L, Tzardi M, Boukovinas I, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pentheroudakis G, Pilpilidis I, Sgouros J, Vassiliou V, Xynogalos S, Ziras N, Karachaliou N, Zoras O, Agalianos C, **Souglakos J** Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. *Ann Gastroenterol*. 2016; 29(1):3-17.
106. Xynos E, Tekkis P, Gouvas N, Vini L, Chrysou E, Tzardi M, Vassiliou V, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Triantopoulou C, Xynogalos S, Karachaliou N, Ziras N, Zoras O, **Souglakos J**; Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the

- Hellenic Society of Medical Oncologists (HeSMO). *Ann Gastroenterol.* 2016 Apr-Jun;29(2):103-26.
107. Christos Dervenis, Evaghelos Xynos, George Sotiropoulos, Nikolaos Gouvas, Ioannis Boukovinas, Christos Agalianos, Nikolaos Androulakis, Athanasios Athanasiadis, Christos Christodoulou, Evangelia Chrysou, Christos Emmanouilidis, Panagiotis Georgiou, Niki Karachaliou, Ourania Katopodi, Panteleimon Kountourakis, Ioannis Kyriazanos, Thomas Makatsoris, Pavlos Papakostas, Demetris Papamichael, George Pechlivanides, Georgios Pentheroudakis, Ioannis Pilpilidis, Joseph Sgouros, Paris Tekkis, Charina Triantopoulou, Maria Tzardi, Vassilis Vassiliou, Louiza Vini, Spyridon Xynogalos, Nikolaos Ziras, John Souglakos. Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). *Ann Gastroenterol.* 2016; 29(4):390-416.
108. Jan Franko, Qian Shi, Jeffrey P Meyers, Timothy S Maughan, Richard A Adams, Matthew T Seymour, Leonard Saltz, Cornelis J A Punt, Miriam Koopman, Christophe Tournigand, Niall C Tebbutt, Eduardo Diaz-Rubio, John Souglakos, Alfredo Falcone, Benoist Chibaudel, Volker Heinemann, Joseph Moen, Aimery De Gramont, Daniel J Sargent, Axel Grothey. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol* 2016 Published Online October 12, 2016 <http://dx.doi.org/10.1016>
109. Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulas V, Souglakos J. PREDICTIVE VALUE OF *ATP7B*, *BRCA1*, *BRCA2*, *PARP1*, *UIMC1 (RAP80)*, *HOXA9*, *DAXX*, *TXN (TRX1)*, *THBS1 (TSP1)*, AND *PRR13 (TXR1)* GENES IN PATIENTS WITH EPITHELIAL OVARIAN CANCER (EOC) WHO RECEIVED PLATINUM-TAXANE FIRST LINE THERAPY. *Pharmacogenomics J* 2016 Oct 25. doi: 10.1038/tpj.2016.63. [Epub ahead of print]
110. Papadakis GZ, Mavroudis D, Georgoulas V, **Souglakos J**, Alegakis AK, Samonis G, Bagci U, Makrigiannakis A, Zoras O Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. *Growth Horm IGF Res.* 2017 Feb 16;33:28-34.
111. Messaritakis I, Stolidis D, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Politaki E, Apostolaki S, **Souglakos J**, Georgoulas V. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). *Sci Rep.* 2017 Mar 28;7:45351.
112. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT1, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinar FF,

- Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. *J Clin Oncol*. 2017 Apr 17;JCO2016715771.
113. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, **Souglakos J**, Georgoulas V. *PLoS One*. 2017 Jul 18;12(7):e0181211. doi: 10.1371/journal.pone.0181211. eCollection 2017.
114. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. *J Natl Cancer Inst*. 2017.
115. Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulas V, Souglakos J. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. *Ann Gastroenterol*. 2018 Jan-Feb;31(1):65-70.
116. de Bree E, Rovers KP, Stamatiou D, Souglakos J, Michelakis D, de Hingh IH. The evolving management of small bowel adenocarcinoma. *Acta Oncol*. 2018 Jan 30:1-11. doi: 10.1080/0284186X.2018.1433321.
117. Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulas V, Souglakos. J Association of *BRCA1*, *ERCC1*, *RAP80*, *PKM2*, *RRM1*, *RRM2*, *TS*, *TSP1* and *TXR1* m RNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non- small cell lung cancer. *Pharmacogenomics J*. 2018 Feb 22. doi: 10.1038/s41397-018-0013-9.
118. Christine Koch, Anna-Maria Schwing, Eva Herrmann, Markus Borner, Eduardo Diaz-Rubio Garcia, Efrat Dotan, Jaime Feliu, Natsuko Okita, John Souglakos, Jolien Tol, Hendrik-Tobias Arkenau, Rainer Porschen, Miriam Koopman, C. Punt, Aimery de Gramont, Christophe Tournigand, Stefan Zeuzem, Joerg Trojan. Bevacizumab-based firstline-chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient-data based meta-analysis. *Oncotarget* 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13
119. Axel Grothey, Alberto F. Sobrero, Anthony F. Shields, Takayuki Yoshino, James Paul, Julien Taieb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Dewi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas,

Jeffrey P. Meyers, Lindsay A. Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J. Sargent, Thierry Andre, Timothy Iveson
Duration of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer *N Eng J Med* 2018;378:1177-88. DOI: 10.1056/NEJMoa1713709

120. A. Sobrero, A. Grothey, T. Iveson, R. Labianca, T. Yoshino, J. Taieb, T. Maughan, M. Buyse, A. Cervantes, J. Meyerhardt, A Shields, I. Souglakos and J.-Y. Douillard
When clinical practice demands that we go beyond statistics: three or six months of adjuvant chemotherapy in patients with colon cancer? *Ann Oncol* 2018 Feb 9. doi: 10.1093/annonc/mdy064. [Epub ahead of print]

Ippokratis Messaritakis, Maria Stogiannitsi, Asimina Koulouridi, Maria Sfakianaki, Alexandra Voutsina, Afroditi Sotiriou, Dimitris Mavroudis, Maria Tzardi, John Souglakos
Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. *PLoS One*. 2018 Jun 8;13(6):e0197327. doi: 10.1371/journal.pone.0197327. eCollection 2018.

122. Natalia Asimakopoulou#, John Souglakos#, Nikolaos Kentepozidis, Athanasios Karampeazis, Athanasios Kotsakis, Nikolaos Ziras, Paris Makrantonakis, Efthimios Prinarakis, Lambros Vamvakas, Vassilis Georgoulas. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). *J Geriatr Oncol*. 2019 Jan;10(1):143-148. doi: 10.1016/j.jgo.2018.08.002. Epub 2018 Oct 23.

123. Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulas V
Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. *Cancer Chemother Pharmacol*. 2018 Nov;82(5):767-775. doi: 10.1007/s00280-018-3666-9. Epub 2018 Aug 9.

124. Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poulios C, Voutsina A, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilas G
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2018 Jun 15. pii: S1533-0028(18)30110-5.

125. Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. *Eur J Cancer*. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

126. Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. Kentepozidis N, Economopoulou P, Lontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulas V. *Ann Gastroenterol*. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14.
127. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. Gourzoulidis G, Maniadakis N, Petrakis D, Souglakos J, Pentheroudakis G, Kourlaba G. *J Comp Eff Res*. 2018 Dec 14. doi: 10.2217/cer-2018-0076.
128. Nikolouzakis TK, Stivaktakis PD, Apalaki P, Kalliantasi K, Sapsakos TM, Spandidos DA, Tsatsakis A, Souglakos J, Tsiaoussis J. Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer. *Oncol Lett*. 2019 Mar;17(3):2703-2712.
129. Thomopoulou K, Tzardi M, Mavroudis D, Souglakos I. A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update. *Case Rep Oncol Med*. 2019 Feb 17;2019:4767019.
130. Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, Mavroudis D, Georgoulas V, Souglakos J. Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. *Cancer Res Treat*. 2019 Mar 20. doi: 10.4143/crt.2019.008. [Epub ahead of print]
131. Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulas V. MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. *Target Oncol*. 2019 Jun 15. doi: 10.1007/s11523-019-00647-3.
132. **Souglakos J**, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulas V. Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. *nn Oncol*. 2019 Jun 22. pii: mdz193. doi: 10.1093/annonc/mdz193.
133. Thomopoulou Konstantina, Rounis Konstantinos, Koutsopoulos Anastasios, Mala Anastasia, Lagoudaki Eleni, Souglakos Ioannis, Agelaki Sofia, Mavroudis Dimitris atal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. *Lung Cancer* 2019 135:29-32.
134. Koliarakis I, Messaritakis I, Nikolouzakis TK, Hamilos G, Souglakos J2, Tsiaoussis J. Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer. *Int J Mol Sci*. 2019 Aug 25;20(17). pii: E4146. doi: 10.3390/ijms20174146.
135. Krasanakis T, Nikolouzakis TK, Sgantzios M, Mariolis-Sapsakos T, Souglakos J, Spandidos DA, Tsitsimpikou C, Tsatsakis A, Tsiaoussis J. Role of anabolic agents

- in colorectal carcinogenesis: Myths and realities (Review). *Oncol Rep.* 2019 Dec;42(6):2228-2244.
136. Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi MA, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E. Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. *Updates Surg.* 2019 Dec;71(4):599-624.

Publications in non SCI Journals

1. EPapadakis, SAgelaki, EBania, AAgeliidou, AHarpidou, ARapti, MAgeliidou, X Tsiafaki, ESarra, J. Souglakos, PhPalamidas, N. Vardakis, V.Georgoulas: Salvage treatment with vinorelbine and ifosfamide in patients with advanced non-small cell lung cancer: a multicenter phase II trial. Journal of BUON 2000; 5: 135-140.
2. S. Kakolyris, N. Androulakis, Ch. Kouroussis, A Kotsakis, J. Souglakos, D Hatzidaki, D Beri, G Samonis, V. Georgoulas. Vinorelbine and tamoxifen as first and second line treatment in elderly patients with advanced breast cancer: Journal of BUON 2000; 5: 219-26.
3. J Souglakos Latest advances in the treatment of metastatic colorectal cancer. Hospital Pharmacy Europe. 2008
4. Georgios Ioannidis, Vassilis Georgoulas, John Souglakos **Targeting VEGF-Biomarkers: A new age in personalized healthcare. Forum of Clinical Oncology. 2011**
5. Konstantinos Tryfonidis, Maria Rovithi, John Souglakos, Dimitris Mavroudis, Vassilis Georgoulas Thrombotic thrombocytopenic purpura in a patient with lung adenocarcinoma: A case report and literature review. Forum of Clinical Oncology, Vol 3, No 1 (2012)
6. Souglakos, J., Karavasilis, V., Tsotra, E., Samantas, E., Sgouros, I., Basta, E., Amarantidis, K., Papandreou, C., Boukovinas, I., Doufexis, D., Labrodimou, G., Ziras, N., Kentepozidis, N., Stathopoulos, G., Stathopoulou, E Pancreatic adenocarcinoma treatment hellenic oncology survey 'PATHOS': Frequency and current treatment modalities of advanced pancreatic adenocarcinoma in Greece Forum of Clinical Oncology 2013 (4), , 11-19
7. Kalikaki, A., Koutsopoulos, A., Sfakianaki, M., Giannikaki, E., Kontopodis, E., Agelaki, S., Souglakos, J., Kotsakis, A., Lagoudaki, E., Georgiou, G.C., Tsakalaki, E., Trypaki, M., Papadimitraki, E., Mavroudis, D., Georgoulas, V., Voutsina, A Detection of EGFR and KRAS mutations in NSCLC patients of greek origin in daily clinical practice Forum of Clinical Oncology 2013; 4 (3), , 44-52
8. Saridaki Z, Asimakopoulou N, Boukovinas I and Souglakos J. How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). Current Colorectal Cancer Reports.2015

Two papers in Greek medical Journals

Book | Chapters

Management of Colorectal Cancers in Older People, Genetic Alterations in Colorectal Cancer in Elderly Patients, Editors R Audisio and D Papamichael, Springer 2012

Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance
Resistance to the anti-EGFR therapy, beyond KRAS, in patients with metastatic colorectal cancer, Editor: B Bonavida, Springer 2013

Participation in three Greek medical books

Member of the Editorial Board

Forum of Clinical Oncology (official Journal of the Hellenic Society of Medical Oncology) since 2005

PLOS ONE Academic Editor since 2013

Annals of Gastroenterology since 2013

Jurnal of Surgical Oncology since 2013

Reviewer for the following journals

Journal	Number of Manuscripts
New England Journal of Medicine	2
Cancer Research	1
PloS ONE	8
International Journal of Cancer	1
British Journal of Cancer	5
Expert Review of Anticancer Therapy	2
Oncology	2
Lung Cancer	2
BMC Cancer	6
Clinical Lung Cancer	1
Clinical Colorectal Cancer	1
Colorectal Cancer	1
World Journal of Gastroenterology	1
Clinical Chimica Acta	2
Cancer Chemotherapy and Pharmacology	3
Acta Biochimica et Biophysica Sinica	1
Future Drugs	3
Future Oncology	3
Expert Opinion	1
Expert Opinion in Pharmacotherapy	1
Journal of Oncology	1
Expert Review of Gastroenterology & Hepatology	1
Medical Oncology	1
Investigational New Drugs	1
Chemotherapy	2
Cancers	1
International Journal of Genetics and Molecular Biology	1
International Journal of Molecular Sciences	1
Current Medical Research and Opinion	1

Cancer Treatment Reviews	2
Immunotherapy	1
Cancer Medicine	1
Onkologie	2
Biomarkers in Medicine	3
Forum of Clinical Oncology	4
Thoracic Cancer	1
Annals of Gastroenterology	2
Chemotherapy Research and Practice	1
Clinical and Experimental Medicine	1
Experimental and Molecular Pathology	1
Clinical Investigation	1
Journal of Cell Science & Therapy	1
European Journal of Clinical Investigation	1
Therapeutic Advances in Medical Oncology	1
The Research and Biology of Cancer	1
Total	81

Patents

Method of Predicting the clinical outcome of patients with Non-Small-Cell-Lung-Cancer treated with an anti-metabolite and an anti-microtubule agent. World Intellectual Property Organization 3/12/2009. Patent No: WO 2009/144155 A1

CONGRESS PROCEEDINGS**Citations:** 105**I. ASCO Proceedings (81 Citations)**

1. Kourousis C, Kakolyris S, Androulakis N, Vamvakas L, Cheras P, Vlata M, Schiza S, Souglakos J, Alissandrakis K, Kavalos S, Hatzidaki D, Samonis G, Georgoulas V : First Line Treatment on Non-Small Lung Carcinoma with Docetaxel and Vinorelbine : A Phase II Study. *J Clin Oncol*: 1996 (May suppl).
2. Kourousis C, Kakolyris S, Cheras P, Androulakis N, Vamvakas L, Vlata M, Kalbakis K, Souglakos J, Alissandrakis K, Schiza S, Kavalos S, Hatzidaki D, Samonis G, Georgoulas : A Preliminary Report of an active salvage chemotherapy combining Vinorelbine, Paclitaxel and CDDP in Anthracycline-Resistant Advanced Breast Cancer. *J Clin Oncol*: 1996 (May suppl).
3. Androulakis N, Dimopoulos A.M., Kourousis C, Kakolyris S, Papadakis E, Apostolopoulou F, Papadimitriou F, Vossos A, Agelidou M, Heras P, Tzannes S, Souglakos J, Hatzidaki D, Georgoulas V : First-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel and cisplatin : a multicenter phase II study. *J Clin Oncol*: 1997 (May suppl).
4. Kakolyris S, Androulakis N, Souglakos J, Kourousis C, Kalbakis K, Kotsakis A, Agelaki S, Hatzidaki D, Samonis G, Georgoulas V : Phase I study with Irinotecan (CPT-11) plus 5-Fluorouracil (5-FU; 4-DY C.I) combination in advanced colon cancer. *J Clin Oncol*: 1998 (May suppl; abstr 1070). **(Citations: 3)**
5. Kakolyris S, Kourousis C, Souglakos J, Androulakis N, Mavroudis D, Kalbakis K, Kotsakis A, Sara E, Agelaki S, Prinianakis G, Vardakis N, Samonis G, Georgoulas V : Phase I study of Irinotecan (CPT-11) cisplatin (CDDP) combination in metastatic Non-Small Cell Lung Cancer (NSCLC). *J Clin Oncol*: 1998 (May suppl; abstr 1884). **(Citations:1)**
6. Mavroudis D, Kourousis C, Malamos N, Potamianou A, Kakolyris S, Alexopoulos A, Androulakis N, Papadakis E, Vlachonikolis J, Kalbakis K, Agelaki S, Kotsakis A, Sara E, Souglakos J, Samonis G, Georgoulas V : A Phase II trial of Docetaxel and Gemcitabine as second line treatment in metastatic Breast Cancer. *J Clin Oncol*: 1998 (May suppl; abstr 607). **(Citations: 3)**.
7. Gianakakis T, Papadouris S, Ziras N, Kourousis C, Mavroudis D, K Kalbakis, Kakolyris S, Agelaki S, Ziani D, Vakaloudi N, Papadakis E, Androulakis N, Souglakos J, Sara E, Hatzidaki D, Georgoulas V : Interim analysis of a Phase I/II study of Docetaxel and Carboplatin (CBP) as 1st line chemotherapy for advanced Non-Small Cell Lung Cancer (NSCLC). *J Clin Oncol*: 1998 (May suppl; abstr 1870).
8. Alexopoulos A, Kourousis C, Kakolyris S, Malamos N, Rigatos G, Androulakis N, Gianakakis T, Papadouris S, Mavroudis D, Sara E, Souglakos J, Hatzidaki D,

- Georgoulas V : A phase I/II study of Docitaxel (D) and Mitoxanthrone (M) in metastatic Breast Cancer. *J Clin Oncol*: 1998 (May suppl; abstr 480).
9. Kourousis C, Kakolyris S, Sameli G, Dimopoulos A M, Papadimitriou C, Genatas K, Tsavaris N, Karabekios S, Staphopoulos G, Kotsakis A, Souglakos J, Samonis G, Georgoulas V: Treatment of advanced Pancreatic Cancer (APC) with Docitaxel (D) : A multicenter phase II study. *J Clin Oncol*: 1998 (May suppl; abstr 1021). **(Citations: 7)**
 10. Georgoulas V, Androulakis N, Kourousis C, Kakolyris S, Papadakis E, Agelidou M, Blazoyiannakis G, Gerogiannis A, Veslemes M, Agelidou A, Dimopoulos A M, Kotsakis A, Souglakos J, Hatzidaki D : Second Line treatment with Paclitaxel (P) and Gemcitabine (G) in patients with Non-Small Cell Lung Cancer (NSCLC) who failed cisPlatin-based chemotherapy. *J Clin Oncol*: 1998 (May suppl; abstr 1800). **(Citations: 7)**
 11. Georgoulas V, Kourousis C, Androulakis N, Kakolyris S, Dimopoulos A M, Papadakis E, Papadimitriou C, Hatzakis K, Bania E, Apostolopoulou F, Tsiadaki X, Alexopoulos A, Souglakos J, Kotsakis A, Vlachonikolis J, Hatzidaki D : Front-Line treatment of advanced Non-Small Cell Lung Cancer (NSCLC) with Docitaxel (D) and Gemcitabine (G) : A multicenter phase II trial. *J Clin Oncol*: 1998 (May suppl; abstr 1819).
 12. D. Mavroudis, J. Souglakos, S. Kakolyris, Ch. Kouroussis, N. Androulakis, S. Agelaki, K Kalbakis , E. Sarra, N Vardakis, D Hatzidaki, P Malliotakis, V. Georgoulas : First line treatment of advanced gastric cancer with docetaxel monotherapy and granulocyte colony-stimulating factor (G-CSF). *J Clin Oncol*: 1999 (May suppl; abstr 997). **(Citations: 3)**
 13. D. Mavroudis, Ch. Kouroussis, S. Kakolyris, N. Androulakis, S. Agelaki, K Kalbakis , E. Sarra, J. Souglakos, D Hatzidaki, G Samonis , V. Georgoulas : Phase I study of gemcitabine/oxaliplatin combination in patients with advanced solid tumors. *J Clin Oncol*: 1999 (May suppl; abstr 842).
 14. S. Agelaki, P Papakostas, G Stathopoulos, G Aravantinos, K Kalbakis , E. Sarra, J. Souglakos, S. Kakolyris, Ch. Kouroussis, N. Androulakis, N Vardakis, V. unresectable or advanced biliary tract carcinomas : a multicenter phase II trial. *J Clin Oncol*: 1999 (May suppl; abstr 1858). **(Citations: 6)**.
 15. Ch. Kouroussis, D. Mavroudis, Th. Giannakakis, N. Ziras, A. Athanasiadis, S. Kakolyris, N. Androulakis, K. Kalbakis, S. Agelaki, J. Souglakos, E. Sarra, N. Vardakis, V. Georgoulas : Biweekly Oxaliplatin (L-OHP) with high-dose Leucovorin (LV) and 5-Fluorouracil (5-FU) 48-hour continuous infusion in pretreated patients with advanced colorectal cancer (CRC). *J Clin Oncol*: 1999 (May suppl; abstr 1111). **(Citations: 3)**
 16. K Kalbakis, Ch. Kouroussis, J. Souglakos, S. Agelaki, D. Mavroudis, N Vardakis, E Kremos, I Kazakou, G Samonis, V Georgoulas : Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) 5-fluorouracil (5-FU) 48-hour

- continuous infusion (CI) in combination with conventional dose of cyclophosphamide (C) in anthracycline and taxane refractory metastatic breast cancer (MBC) patients. A phase II study. *J Clin Oncol*: 2000; 19 (May suppl; abstr 453).
17. S. Agelaki, C Kouroussis, D. Mavroudis, K Kalbakis, L Souglakos, D Reppa, I Isbarah, I Mixaki, V Georgoulis : A phase I study of Docetaxel (D) and Oxaliplatin (L-OHP) as front line treatment in metastatic breast cancer (MBC) and non-small lung cancer (NSCLC). *J Clin Oncol*: 2000; 19 (May suppl; abstr 443). **(Citations: 1)**
 18. L. Souglakos, C Kouroussis, N. Ziras, N Malamos, A Potamianou, D. Mavroudis, K Kalbakis, N Vardakis, E Kremos, G Samonis, V Georgoulis : First line treatment with 5-Fluorouracil (5-FU), Leucovorin (LV) and Oxaliplatin (L-OHP) in advanced colorectal cancer (ACC) : A multicenter phase II study. *J Clin Oncol*: 2000; 19 (May suppl; abstr 1189). **(Citations: 1)**
 19. C Kouroussis, L. Souglakos, Th. Giannakakis, A. Athanasiadis, N. Ziras, P Panopoulos, S. Kakolyris, N. Androulakis, I Mixaki, E Sarra, V Georgoulis : Biweekly Oxaliplatin (L-OHP) with high-dose Leucovorin (LV) and 5-Fluorouracil (5-FU) 48-hour continuous infusion in irinotecan pretreated patients with advanced colorectal cancer (CRC). *J Clin Oncol*: 2000; 19 (May suppl; abstr 1203). **(Citations: 5)**
 20. Th. Giannakakis, S Kakolyris, P Papadouris, I Theodoropoulos, K Kalbakis, N. Androulakis, L. Souglakos, S. Agelaki, P Malliotakis, V Georgoulis : Phase II study of Docetaxel (TXT) and Carboplatin (CBDCA) combination advanced non-small cell lung cancer (NSCLC). *J Clin Oncol*: 2000; 19 (May suppl; abstr 2102).
 21. S Kakolyris, N Androulakis, S. Agelaki, D Mavroudis, L. Souglakos, N Vardakis, D Reppa, G Samonis, V Georgoulis : Salvage treatment of taxanes refractory advanced non-small cell lung cancer (NSCLC) with cisplatin plus irinotecan (CPT-11) combination. *J Clin Oncol*: 2000; 19 (May suppl; abstr 2121).
 22. Pavlos Papakostas, Charalambos Kouroussis, Nikolaos Androulakis, George Samelis, Gerasimos Aravantinos, Kostas Kalbakis, Evanthia Sarra, John Souglakos, Stylianos Kakolyris, Vassilis Georgoulis First Line Chemotherapy with Docetaxel for Unresectable or Metastatic Carcinoma of the Biliary Tract. A Multicenter Phase II Study. *J Clin Oncol*: 2001; 20 (May suppl; abstr 610).
 23. Theodore D. Giannakakis, Stylianos Kakolyris, Manolis Michailakis, Savvakis Papadouris, Kostas Malas, Kostas Kalbakis, Nikolaos Androulakis, John Souglakos, Sophia Agelaki, Lambros Vamvakas, Nikolaos Vardakis, Athanasios Pallis, Vassilis Georgoulis. Final Results of a Phase II Study of Docetaxel (TXT) and Carboplatin (CBDCA) Combination in Advanced Non-Small Cell Lung Cancer (NSCLC). An Ongoing Study. *J Clin Oncol*: 2001; 20 (May suppl; abstr 2845).
 24. John Souglakos, Stylianos Kakolyris, Athanasios Athanasiadis, Charalambos Kouroussis, Dimitrios Mavroudis, Nikolaos Xenidis, Athanasios Pallis, Helen Adamtziki, Vassilis Georgoulis. Irinotecan (CPT-11) Plus Oxaliplatin (LOHP) Plus Infusional 5-Fluorouracil (5-FU) and Leukovorin (LV) as First Line Treatment for

- Metastatic Colorectal Cancer (MCC): a Phase II Trial. *J Clin Oncol*: 2001; 20 (May suppl; abstr 2223).
25. Charalambos Kouroussis, Stylianos Kakolyris, Dimitrios Mavroudis, Kostas Kalbakis, John Souglakos, Lambos Vamvakas, Kostas Malas, Vassiliki Bozionelou, Nikolaos Androulakis, Helen Adamtziki, Nikolaos Xenidis, Vassilis Georgoulas. A Phase I Study of Weekly Docetaxel (D) and Gemcitabine (G) in Advanced Non-Small Cell Lung Cancer. *J Clin Oncol*: 2001; 20 (May suppl; abstr 2844).
26. J. Souglakos, A. Athanasiadis, P. Ginopoulos, Th. Giannakakis, K. Syrigos, Ch. Kouroussis, N. Androulakis, S. Kakolyris, N. Vardakis, V. Georgoulas. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5-FU) (FOLFOXIRI) compared with CPT-11, LV and 5-FU (FOLFIRI) as first-line treatment for metastatic colorectal cancer: preliminary safety and efficacy results of a multicenter randomized trial. *J Clin Oncol*: 2002; 21 (May suppl; abstr 608) (**Citations: 8**)
27. Sophia Agelaki, Kostas Kalbakis, Charalambos Kouroussis, Nikos Androulakis, Stelios Kakolyris, John Souglakos, Nikos Vardakis, Vassiliki Bozionelou, Dimitrios Mavroudis, Vassilis Georgoulas. Phase I study of biweekly oxaliplatin (LOHP) in combination with weekly administration of leukovorin (LV) and continuous 5-fluorouracil (5-FU) infusion in patients with advanced solid malignancies. *J Clin Oncol*: 2002; 21 (May suppl; abstr 2191)
28. Nikos Androulakis, Charalambos Kouroussis, Stelios Kakolyris, Kostas Kalbakis, Sophia Agelaki, Nikos Vardakis, Nikos Xenidis, Athanasios Pallis, Helen Adamtziki, John Souglakos, George Samonis, Vassilis Georgoulas. Phase I study of capecitabine combination with radiotherapy as adjuvant treatment for operable rectal cancer. *J Clin Oncol*: 2002; 21 (May suppl; abstr 2297)
29. J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Chrostophilakis, A. Kotsakis, V. Georgoulas. Combination of Irinotecan (Cpt-11) Plus Oxaliplatin (L-Ohp) As First Line Treatment In Locally Advanced Or Metastatic Gastric Cancer: A Multicenter Phase Ii Trial. *J Clin Oncol*: 2003; 22 (May suppl; abstr 1288). (**Citations: 3**)
30. J. Souglakos, N. Ziras, A. Polyzos, A. Athanasiadis, S. Kakolyris, T. Giannakakis, E. Tselepatiotis, K. Kalbakis, N. Vardakis, V. Georgoulas. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial. *J Clin Oncol*: 2004; 22 (July 14s; abstr 3532). (**Citations: 19**)
31. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer *J Clin Oncol*: 2004; 22 (July 14s; abstr 7148). (**Citations: 1**)
32. J. Souglakos, N. Androulakis, M. Tzardi, A. Kalykaki, A. Argyraki, N. Vardakis, G. Sfakiotaki, K. Kalbakis, A. Kotsakis, D. Mavroudis, V. Georgoulas. Cetuximab plus

- Capecitabine (CAP) and Oxaliplatin (LOHP) (CAPOX) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after Oxaliplatin-based chemotherapy. 2006 Gastrointestinal Cancer Symposium; Abstract No 235. **(Citations: 3)**.
33. N. Androulakis, I. Boukovinas, V. Bozionelou, A. Kalykaki, A. Potamianou, A. Pallis, L. Vamvakas, I. Gkioulbasanis, L. Souglakos, G. Sfakiotaki. Sequential administration of cisplatin (c), gemcitabine (g) and docetaxel (d), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study. *J Clin Oncol*: 2006; 24(June 18s; abstr 14574). **(Citations: 1)**.
34. L. Souglakos, K. Kalbakis, N. Vamvakas, A. Kalykaki, A. Kotsakis, S. Agelaki, A. Karampeazis, J. Gioulbasanis, V. Georgoulas. Cetuximab plus bevacizumab in patients (pts) with metastatic colorectal cancer (mCRC) who have failed on irinotecan, oxaliplatin and fluoropyrimidines-based chemotherapy. *J Clin Oncol*: 2007; 25 (June 18s; abstr 14576). **(Citations: 1)**.
35. A. Pallis, A. Voutsina, A. Kalikaki, A. Koutsopoulos, L. Souglakos, C. Christophylakis, N. Kentepozidis, S. Giassas, D. Mavroudis, V. Georgoulas. Correlation of gefitinib efficacy and detection of new EGFR mutation variants in pre-treated patients (pts) with advanced non- small cell lung cancer (NSCLC). *J Clin Oncol*: 2007; 25 (June 18s; abstr 18062).
36. N. Ziras, A. Polyzos, S. Kakolyris, N. Xenidis, N. Kentepozidis, A. Athanasiadis, I. Stergiou, N. Androulakis, L. Vamvakas, L. Souglakos. CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 15008)
37. C. Papadaki, M. Trypaki, A. Koutsopoulos, I. Boukovinas, D. Mavroudis, E. Stathopoulos, M. Sfakianaki, V. Georgoulas, L. Souglakos. Association of tumoral BRCA1, RRM1 and RRM2 mRNA expression levels with clinical responses to front-line docetaxel/gemcitabine (DG) chemotherapy in patients with non-small cell lung cancer (NSCLC). *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 8112).
38. L. Souglakos, C. Papadaki, M. Trypaki, A. Koutsopoulos, E. Stathopoulos, D. Mavroudis, M. Sfakianaki, V. Georgoulas. Use of tumoral expression TXR1 and TSP1 to predict overall survival of patients with non-small-cell-lung-cancer (NSCLC) treated with first line chemotherapy. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 19011).
39. L. Souglakos, J. Philips, S. Marwah, M. Silver, M. Tzardi, J. Silver, E. Kwak, V. Georgoulas, M. H. Kulke, R. Shivdasani. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. 2009 Gastrointestinal Cancers Symposium abstr 293.
40. L. Souglakos, Z. Saridaki, M. Tzardi, D. Papadatos, Patsos, E. Bairaktari, H. Arvanity, E. Stathopoulos, V. Georgoulas, Use of BRAF mutations, microsatellite instability

- status, and cyclin D1 expression to predict metastatic colorectal (mCRC) patients' outcome. 2010 Gastrointestinal Cancers Symposium abstr 355.
41. L. Sougklakos, I. Messaritakis, N. K. Vardakis, C. Papadaki, M. Sfakianaki, S. Apostolaki, M. Perraki, J. Koutroubakis, D. Mavroudis, V. Georgoulis Predictive and prognostic value of peripheral blood CEA mRNA-positive cells detected by real-time polymerase chain reaction in patients with early-operable colorectal cancer (CRC) 2010 Gastrointestinal Cancers Symposium abstr 338.
 42. N. Ziras, A. Polyzos, N. Xenidis, A. Kalykaki, N. E. Androulakis, P. Papakotoulas, N. K. Kentepozidis, P. Makrantonakis, S. Xynogalos, L. Sougklakos. CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC). J Clin Oncol 28:7s, 2010 (suppl; abstr 3542).
 43. C. Papadaki, E. Tsaroucha, L. Kaklamanis, D. Mavroudis, E. Lagoudaki, M. Trypaki, E. Tsakalaki, V. Georgoulis, L. Sougklakos Correlation of pharmacogenetic markers with docetaxel-based chemotherapy resistance in patients with advanced/metastatic non-small cell lung cancer. J Clin Oncol 28:7s, 2010 (suppl; abstr 7615)
 44. Ch. Papadaki, Z Saridaki, M Tzardi, , M Sfakianaki, G Sfakiotaki, El Tsakalaki, M. Trypaki, Ip Messaritakis, E. Stathopoulos, D Mavroudis, V Georgoulis, L Sougklakos. **PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC)** 2011 Gastrointestinal Cancers Symposium abstr 434.
 45. Z Saridaki, M Tzardi, Ch. Papadaki, M Sfakianaki, F. Pega, Ar. Kalykaki, El Tsakalaki, M. Trypaki, Ip Messaritakis, E. Stathopoulos, D Mavroudis., V Georgoulis, J Sougklakos. Impact of *KRAS*, *BRAF*, *PIK3CA* mutations, PTEN, *AREG*, *EREG* expression and skin rash in metastatic colorectal cancer patients treated with cetuximab-containing salvage treatment. 2011 Gastrointestinal Cancers Symposium abstr 445.
 46. A Athanasiadis, J Boukovinas, M Sfakianaki, Z Saridaki, Ch Papadaki, M Tzardi, N Androulakis, A Polyzos, V Georgoulis, L. Sougklakos FOLFIRI (Folinic acid, 5 Fluorouracil, Irinotecan) + chemoradiation (CRT) with 5-Fluorouracil (5FU) as adjuvant treatment for patients with operable gastric cancer (OGC): A feasibility study with pharmacogenetic analysis. 2011 Gastrointestinal Cancers Symposium abstr 44.
 47. L. Sougklakos, N. K. Vardakis, E. Kampouraki, I. Kotortsi, N. E. M. Androulakis, L. Vamvakas, K. Kalbakis, D. Hatzidaki, D. Mavroudis, V. Georgoulis Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC) J Clin Oncol 29: 2011 (suppl; abstr e14027).
 48. N. Karachaliou, C. Papadaki, E. Lagoudaki, M. Sfakianaki, D. Mavroudis, M. Trypaki, E. Stathopoulos, V. Georgoulis, L. Sougklakos Prognostic and/or predictive value of *ERCC1*, *BRCA1*, *ATP7B*, *TOPO1*, *TOPO2A*, and *TOPO2B* genes in patients with small cell lung cancer (SCLC). J Clin Oncol 29: 2011 (suppl; abstr e21049)

49. R. Geva, B. V. Jensen, G. Fountzilas, T. Yoshino, D. Paez, C. Montagut, I. Souglakos, F. Cappuzzo, A. Cervantes-Ruiperez, D. Papamichael, M. Frattini, B. Vincenzi, T. Macarulla, F. Loupakis, K. G. Spindler, C. Qvortrup, F. Ciardiello, S. Tejpar. An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. *J Clin Oncol* 29: 2011 (suppl; abstr 3528).
50. Chara Papadaki, Maria Sfakianaki, Zacharenia Saridaki, Georgios Giagas, Kyriakos Mpananis, Maria Tzardi, Eleftheria Tsakalaki, Maria Trypaki, Vassilis Georgoulas, Ioannis Souglakos PKM2 mRNA expression to predict disease recurrence in patients with stage II or III colon cancer treated with oxaliplatin in combination with fluoropyrimidines. *J Clin Oncol* 30, 2012 (suppl 4; abstr 468)
51. Chara Papadaki, Niki Karachaliou, Eleni Lagoudaki, Maria Trypaki, Maria Sfakianaki, Anastasios Koutsopoulos, Dimitrios Mavroudis, Efstathios Stathopoulos, Vassilis Georgoulas, John Souglakos. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-ii, TOPO-iib, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide. *J Clin Oncol* 31, 2013 (suppl; abstr 7594).
52. Qian Shi, Aimery De Gramont, Marc E. Buyse, Axel Grothey, Hans-Joachim Schmoll, Matthew T. Seymour, Richard A. Adams, Leonard Saltz, Richard M. Goldberg, Cornelis J. A. Punt, Jean-Yves Douillard, J. Randolph Hecht, Herbert Hurwitz, Eduardo Diaz-Rubio, Rainer Porschen, Niall C. Tebbutt, Charles S. Fuchs, John Souglakos, Alfredo Falcone, Daniel J. Sargent, for the ARCAD Group. Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. *J Clin Oncol* 31, 2013 (suppl; abstr 3533).
53. Dirkje Willemien Sommeijer, Qian Shi, Jeffrey P Meyers, Katrin Marie Sjoquist, Paulo Marcelo Hoff, Matthew T. Seymour, James Cassidy, Richard M. Goldberg, Jean-Yves Douillard, J. Randolph Hecht, Herbert Hurwitz, Christophe Tournigand, Niall C. Tebbutt, Enrique Aranda, John Souglakos, Fairouz F. Kabbinavar, Benoist Chibaudel, Aimery De Gramont, Daniel J. Sargent, John Raymond Zalberg, for the ARCAD Group. Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. *J Clin Oncol* 31, 2013 (suppl; abstr 3520).
54. Everardo D. Saad, Elisabeth Coart, Dirkje Willemien Sommeijer, Qian Shi, John Raymond Zalberg, Tomasz Burzykowski, Jeffrey P. Meyers, Paulo Marcelo Hoff, J. Randolph Hecht, Herbert Hurwitz, Jolien Tol, Niall C. Tebbutt, Charles S. Fuchs, Eduardo Diaz-Rubio, John Souglakos, Alfredo Falcone, Fairouz F. Kabbinavar, Daniel J. Sargent, Aimery De Gramont, Marc E. Buyse, for the ARCAD Group. Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 3578)
55. Katrin Marie Sjoquist, Carsten Bokemeyer, Lindsay A. Renfro, John Simes, Niall C. Tebbutt, Stephen John Clarke, Richard Adams, Cornelis J. A. Punt, Eric Van Cutsem, Jean-Yves Douillard, J. Randolph Hecht, Volker Heinemann, Ioannis Souglakos,

- Eduardo Diaz-Rubio, Rainer Porschen, Jeffrey P. Meyers, Wilson I. Gonsalves, Daniel J. Sargent, Aimery De Gramont, John Raymond Zalcborg, Fondation Aide et Recherche en Cancerologie Digestive (ARCAD) Group. Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients. *J Clin Oncol* 33, 2015 (suppl; abstr 3555).
56. Chara Papadaki, Spyros Pontikakis, Eleni Lagoudaki, Maria Trypaki, Filippou Koinis, Maria Tzardi, Linda Giannikaki, Maria Sfakianaki, Antonia Kalykaki, Dimitrios Mavroudis, Vassilis Georgoulas, Ioannis Souglakos. PKM2 and CD44 tumoral expression to predict the effectiveness of front-line paclitaxel and carboplatin chemotherapy in epithelial ovarian cancer. *J Clin Oncol* 33, 2015 (suppl; abstr e16564).
57. Ippokratis Messaritakis, Dimitrios Stolidis, Eleni Politaki, Stella Apostolaki, Eleftheria- Kleio Dermitzaki, Maria Sfakianaki, Athanasios Kotsakis, Sofia Agelaki, Lampros Vamvakas, Kostas Kalbakis, Eleni Lagoudaki, Dimitrios Mavroudis, Vassilis Georgoulas, Ioannis Souglakos. Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features. *J Clin Oncol* 33, 2015 (suppl; abstr 7573)
58. Jan Franko, Qian Shi, Jeffrey P. Meyers, Volker Heinemann, Alfredo Falcone, Niall C. Tebbutt, Tim Maughan, Matthew Seymour, Leonard Saltz, Christophe Tournigand, Eduardo Diaz-Rubio, Ioannis Souglakos, Benoist Chibaudel, Joseph Moen, Aimery De Gramont, Richard A. Adams, Daniel J. Sargent, Axel Grothey. Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database. *J Clin Oncol* 34, 2016 (suppl 4S; abstr 656)
59. Jan Franko, Qian Shi, Jeffrey P. Meyers, Volker Heinemann, Alfredo Falcone, Niall C. Tebbutt, Tim Maughan, Matthew Seymour, Leonard Saltz, Christophe Tournigand, Eduardo Diaz-Rubio, Ioannis Souglakos, Benoist Chibaudel, Joseph Moen, Aimery De Gramont, Richard A. Adams, Daniel J. Sargent, Axel Grothey. Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database. *J Clin Oncol* 34, 2016 (suppl 4S; abstr 656).
60. John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris, Nikolaos Ziras, Nikolaos E. M. Androulakis, Alexandros Ardavanis, Nikolaos K. Kentepozidis, Michael Vaslamatzis, Athanasios Athanasiadis, Athina Christopoulou, Paris Makrantonakis, Aristidis Polyzos, Dimitrios Mavroudis, Anastasia Mala, Aggeliki Kalisperi, Spyros Xynogalos, Ioannis I. Varthalitis, Charalambos Kouroussis, Efthimios Prinarakis, Vassilis Georgoulas. The Greek participation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients' characteristics and safety analysis. *J Clin Oncol* 35, 2017 (suppl 4S; abstract 740).
61. Qian Shi, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Souglakos, Rachel Kerr, Roberto Labianca, Jeffrey

- A. Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Lindsay A. Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Daniel J. Sargent, Timothy Iveson. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. *J Clin Oncol* 35, 2017 (suppl; abstr LBA1). Presented in plenary session.
62. John Souglakos, Ioannis Boukovinas, Spyros Xynogalos, Stylianos Kakolyris, Nikolaos Ziras, Michael Vaslamatzis, Alexandros Ardavanis, Athanasios Athanasiadis, Nikolaos E. M. Androulakis, Nikolaos K. Kentepozidis, Athina Christopoulou, Paris Makrantonakis, Ioannis I. Varthalitis, Charalampos Christofyllakis, Christos E. Emmanouilides, Dimitrios Mavroudis, Efthimios Prinarakis, Aggeliki Kalisperi, Dora Hatzidaki, Vassilis Georgoulas Three versus six months adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for patients with stage III colon cancer: The Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant (IDEA) chemotherapy project. *ASCO-GI 2018 J Clin Oncol* 36, 2018 (suppl 4S; abstr 730)
63. Timothy Iveson, Alberto F. Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang-Shu Ou, Jeffery P. Meyers, Qian Shi, Mark P. Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels Henrik Hollander, Valter Torri, Kentaro Yamazaki, Vassilis Georgoulas, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). *J Clin Oncol* 37, 2019 (suppl; abstr 3501). Oral Presentation at Colorectal Cancer Session
64. Ioannis Souglakos, Ioannis Boukovinas, Spyros Xynogalos, Stylianos Kakolyris, Nikolaos Ziras, Michael Vaslamatzis, Athanasios Athanasiadis, Alexandros Ardavanis, Nikolaos E. M. Androulakis, Athina Christopoulou, Paris Makrantonakis, Iliada Bompolaki, Charalampos Christofyllakis, Nikolaos K. Kentepozidis, Christos E. Emmanouilides, Charalambos Kouroussis, Efthimios Prinarakis, Aggeliki Kalisperi, Dimitrios Mavroudis, Vassilis Georgoulas Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. *J Clin Oncol* 37, 2019 (suppl; abstr 3500). Oral Presentation at Colorectal Cancer Session

65. Zacharenia Saridaki, Emmanouil S. Saloustris, Nikolaos Tsoukalas, Thomas Makatsoris, Georgios Lypas, Haralabos Kalofonos, Athina Christopoulou, Iliada Bompolaki, Ioannis Souglakos, Evangelos Voulgaris, Athanasios Karampeazis, Christos Papandreou, Athanasios Anagnostopoulos, Eleni P. Galani, Konstantinos Ballasis, Flora Zagouri, Georgios Rizos, Athanasios Athanasiadis, Ioannis I. Varthalitis, Ioannis Boukovinas. Screening of colorectal cancer (CRC) patients for lynch syndrome (LS) emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). *J Clin Oncol* 37, 2019 (suppl; abstr e13141)

II. AACR Proceedings

1. A Voutsina, A Koutsopoulos, A Kalykaki, J Souglakos, A Pallis, M Trypaki, D Mavroudis, V Georgoulis Novel EGFR mutations in patients with Non Small Cell Lung Cancer (NSCLC) and correlation with sensitivity to Gefitinib. **AACR 2006 Abstr # 4408.**
2. A Kalykaki, A Voutsina, J Souglakos, A Koutsopoulos, M Trypaki, D Mavroudis, V Georgoulis. EGFR and k-Ras mutation status in matched primary and metastatic tumors from patients with NSCLC. **AACR 2007 Abstr # 5022.**
3. A Voutsina, A Kalykaki, A Koutsopoulos, J Souglakos, M Trypaki, D Mavroudis, V Georgoulis. Novel EGFR mutations in primary tumors predict response to first line chemotherapy of patients with NSCLC. **AACR 2007 Abstr # 5033.**

III. ESMO/ECCO Proceedings (20 Citations)

1. Panagos G, Mavroudis D, Potamianou A, Malamos N, Kourousis C, Kakolyris S, Souglakos J, Sara E, Gianakakis T, Georgoulis V : Phase I of Docetaxel and Epirubicin in advanced breast cancer. **23rd Congress of the ESMO, Athens, November 6 - 10, 1998.**
2. Ziras N, Gianakakis T, Androulakis N, Mavroudis D, Kakolyris S, Tsitoura P, Kourousis C, Souglakos J, Perisinaki G, Georgoulis V : Second line treatment of metastatic colon cancer with oxaliplatin and high dose 5 - Fluorouracil and folinic acid : A preliminary report of a confirmation phase II trial of the Greek Cooperative Group for the Study of Colorectal Cancer. **23rd Congress of the ESMO, Athens, November 6 - 10, 1998.**
3. Agelaki S, Mavroudis D, Kakolyris S, Kourousis C, Kalbakis K, Sara E, Souglakos J, Kalikaki T, Perisinaki G, Kois S, Georgoulis V : Phase I study of weekly Paclitaxel in Advanced Solid Tumors : A Preliminary Report. **23rd Congress of the ESMO, Athens, November 6 - 10, 1998.**

4. Gianakakis T, Papadouris S, Ziras N, Kourousis C, Mavroudis D, K Kalbakis, Kakolyris S, Agelaki S, Ziani D, Vakaloudi N, Papadakis E, Androulakis N, Souglakos J, Sara E, Hatzidaki D, Georgoulis V : A Phase I/II study of Docetaxel and Carboplatin (CBP) as 1st line chemotherapy for advanced Non-Small Cell Lung Cancer (NSCLC). **23rd Congress of the ESMO, Athens, November 6 - 10, 1998.**
5. Alexopoulos, N. Malamos, Th. Giannakakis, D. Mavroudis, G. Panagos, S. Agelaki, Ch. Kosmas, J. Souglakos, N. Vardakis, F. Apostolaki : Treatment of metastatic breast cancer with intensified combination of docetaxel and mitoxantrone: A multicenter phase II trial. **23rd Congress of the ESMO, Athens, November 6 - 10, 1998**
6. S Kakolyris, Ch. Kouroussis, J. Souglakos, N. Androulakis, D. Mavroudis, K. Kalvakis, A. Kotsakis, E. Sara, S. Agelaki, G. Samoni, V. Georgoulis : Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC). **23rd Congress of the ESMO, Athens, November 6 - 10, 1998(Citations: 1)**
7. D. Mavroudis, S. Agelaki, K Kalbakis , Ch. Kouroussis, S. Kakolyris, N. Androulakis, J. Souglakos, N Vardakis, G Samomis , V. Georgoulis : A dose finding and toxicity study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors. **ECCO 10 VIENNA ,SEPTEMBER 12-16,1999. (Citations: 1)**
8. Ch. Kouroussis, N Androulakis, K Kalbakis, S. Kakolyris, D. Mavroudis, S. Agelaki, J. Souglakos, N. Vardakis, G Samonis, V Georgoulis : A phase I study of Docetaxel (D) and Oxaliplatin (L-OHP) as front line treatment in metastatic breast and non-small lung cancer (NSCLC) : Preliminary results. **ECCO 10 VIENNA ,SEPTEMBER 12-16,1999. (Citations: 1)**
9. K Kalbakis, S. Agelaki, N Androulakis, S. Kakolyris, Ch. Kouroussis, N Androulakis, D. Mavroudis, J. Souglakos, I Isbarah, G Samonis, V Georgoulis : Salvage chemotherapy with high-dose leukovorin (lv) and 5-fluorouracil (5-fu) 48-hour continuous infusion (ci) in combination with conventional dose of cyclophosphamide (c) in anthracycline/taxane refractory metastatic breast cancer (mbc) patients. A phase II study. **ECCO 10 VIENNA ,SEPTEMBER 12-16,1999.**
10. J. Souglakos, K Kotsakis, E Sarra, S Kakolyris, Ch. Kouroussis, S. Agelaki, N Vardakis, K Kalbakis, V Georgoulis, G Samonis : Non neutropenic infections associated with docetaxel containing chemotherapy in patients with advanced solid tumors. . **ECCO 10 VIENNA ,SEPTEMBER 12-16,1999.**
11. J. Souglakos, C Kouroussis, N. Ziras, N Malamos, A Potamianou, D. Mavroudis, S Kakolyris, N Androulakis, N Vardakis, V Georgoulis : First line treatment with 5-Fluorouracil (5-FU), Leucovorin (LV) and Oxaliplatin (L-OHP) in advanced colorectal cancer (ACC) : A multicenter phase II study. **25th ESMO Congress Hamburg 2000. (Citations: 2)**
12. N Vardakis, J. Souglakos, K Kalbakis, S Agelaki, D. Mavroudis, S Kakolyris, L Vamvakas, A Pallis, G Samonis, V Georgoulis : Weekly irinotecan and Leucovorin

- and 5-Fluorouracil (AIO schedule) in pretreated patients with advanced colorectal cancer: Preliminary results. **25th ESMO Congress Hamburg 2000. (Citations: 3)**
13. C Kouroussis, S Kakolyris, D Mavroudis, K Kalbakis, G Stathopoulos, J. Souglakos, L Vamvakas, N Xenidis, G Samonis, V Georgoulis : Weekly administration of docetaxel (D) and gemcitabine (G) as front line chemotherapy of patients with non-small cell lung cancer : An ongoing phase I study. **25th ESMO Congress Hamburg 2000.**
 14. Th. Giannakakis, S Kakolyris, P Papadouris, D Mavroudis, K Kalbakis, J. Souglakos, S. Agelaki, F Passam I Mixaki, V Georgoulis : A multicenter phase II study of Docetaxel (TXT) and Carboplatin (CBDCA) combination in advanced non-small cell lung cancer (NSCLC). A Preliminary analysis. **25th ESMO Congress Hamburg 2000.**
 15. K Kalbakis, C Kouroussis, J. Souglakos, S Kakolyris, S Agelaki, D Mavroudis, D Reppa, V Bozionelou, Irini Kazakou, G Samonis, V Georgoulis : Salvage chemotherapy with cyclophosphamide and high-dose leukovorin (lv) and a 48-hour continuous infusion (CI) 5-fluorouracil (5-FU) in anthracycline-taxane refractory metastatic breast cancer (MBC). A phase II study. **25th ESMO Congress Hamburg 2000.**
 16. D Mavroudis , Ch Kouroussis, S Kakolyris , J. Souglakos, N. Vardakis, N. Androulakis, G Samonis, V Georgoulis. A phase I study of Caelyx-Oxaliplatin combination in patients with advanced solid tumors. **ECCO 11 LISBON, 2001.**
 17. J. Souglakos, D Mavroudis, S Kakolyris, Ch Kouroussis, N Vardakis, N Androulakis, S Agelaki, K Kalbakis, D Tsetis, N Athanasiadis, G Samonis, V Georgoulis. A triplet combination with irinotecan (CPT-11) plus oxaliplatin (I-OHP) plus continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) as first line treatment in metastatic colorectal cancer (mcc): a multicenter phase II trial. **ECCO 11 LISBON, 2001. (Citations: 2)**
 18. G Stathopoulos, S Rigatos, N. Androulakis, J. Souglakos, Ch. Kouroussis, AM Dimopoluos, G Aravantinos, Th Giannakakis, G Fountzilias, J Stathopoulos, V Georgoulis. Multicenter phase II trial of first line Irinotecan (CPT-11) and Gemcitabine (GMB) in patients with unresectable pancreatic cancer. **ECCO 11 LISBON, 2001. (Citations: 1).**
 19. N. Androulakis, Ch. Kouroussis, D Mavroudis , S Agelaki, J. Souglakos, N. Vardakis, A Pallis, V Bozionelou, V Georgoulis. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. **ECCO 11 LISBON, 2001**
 20. Maria Anatoliotaki, V. Valatas, H. Apostolakou, D. Mavroudis, J. Souglakos, S. Agelaki, V. Georgoulis, G. Samonis· Bloodstream infections in patients with solid tumors: Risk factors, microbial spectrum and outcome **ESMO 2002**
 21. Nick Vardakis, M. Perraki, S. Apostolaki, J. Souglakos, D. Mavroudis, G. Vogiatzis, V. Georgoulis Different schedules of edrocolomab administration in colorectal cancer patients with CEA-mRNA-positive cells in the peripheral blood **ESMO 2002**

22. C. Kouroussis, J. Souglakos, K. Kalbakis, N. Vardakis, K. Malas, S. Agelaki, L. Vamvakas, N. Androulakis, V. Georgoulis Salvage chemotherapy with leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with cyclophosphamide (CPM) and vinorelbine (VNL) in pretreated patients with metastatic breast cancer (MBC) **ESMO 2002**
23. Vassiliki Bozionelou, G. Stathopoulos, K. Syrigos, A. Polyzos, Ch. Kouroussis, J. Souglakos, A. Potamianou, G. Fountzilas, A. Athanasiadis, V. Georgoulis. The combination of gemcitabine (GEM) and capecitabine (CAP) as first line treatment, in patients with unresectable pancreatic cancer: Preliminary results of a multicenter phase II study **ESMO 2002 (Citations: 1)**
24. J. Souglakos, L. Vamvakas, Z. Saridaki, I. Kazakou, A. Pallis, V. Georgoulis Increase Incidence Of Central Nervous System (Cns) Involvement For Patients With Breast Cancer (Bc) Treated With Taxanes Based Chemotherapy *Ann Oncol*, **2004; 15 (SUPPL. 3)**.
25. Athanasiadis A., Souglakos J., Potamianou A. Preliminary results of phase II study with xelox as salvage treatment metastatic colorectal cancer (MCC) pretreated with FOLFIRI *Ann Oncol*, **2004; 15 (SUPPL. 3) (Citations: 2)**
26. D. Mavroudis, J. Souglakos, T. Kalikaki, N. Androulakis, S. Agelaki, T. Kotsakis, N. Vardakis, K. Kalbakis, V. Georgoulis. A phase I-II study of imatinib mesylate (Glivec) in patients with relapsed or refractory small cell lung cancer (SCLC) **EJC SUPPLEMENTS. 2005**
27. V. Georgoulis, D. Hatzidaki, D. Mavroudis, A. Alegegis, J. Souglakos, N. Kentepozidis, I. Vlachonikolis, for Hellenic Oncology, Research Group (HORG). Effect of second-line chemotherapy on survival of patients with advanced non-small cell lung cancer pretreated with docetaxel-based chemotherapy: A retrospective survival analysis. **EJC SUPPLEMENTS 2005**
28. N. Androulakis, I. Boukovinas, V. Bozionelou, A. Kalykaki, A. Potamianou, A. Pallis, L. Vamvakas, I. Gioulbasanis, J. Souglakos, G. Sfakiotaki. Sequential administration of cisplatin (C), gemcitabine (G) and docetaxel (D), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study. *Ann Oncol* **Volume: 17 Pages: 151-151 Supplement: Suppl. 9, 2006.**
29. A. Voutsina, A. Koutsopoulos, A. Kalykaki, J. Souglakos, A. Pallis, M. Trypaki, D. Mavroudis, V. Georgoulis. Novel EGFR mutations in patients with non-small cell lung cancer (NSCLC) and correlation with sensitivity to gefitinib. *ANNALS OF ONCOLOGY* **Volume: 17 Pages: 250-251 Supplement: Suppl. 9, 2006**
30. J. Souglakos, D. Papadatos-Pastos, M. Tzardi, Z. Saridaki, N. Zois, M. Perraki, D. Mavroudis, V. Georgoulis. Correlation of microsatellite instability (MSI) status with clinical parameters and treatment outcomes for patients with metastatic colorectal cancer (MCC) treated with a triplet combination with irinotecan (CPT-11), oxaliplatin (L-OHP) plus bolus and infusional 5FU/leucovorin (degramont regimen)-FOLFOXIRI

ANNALS OF ONCOLOGY Volume: 17 Pages: 250-251 Supplement: Suppl. 9, 2006

31. C Emmanuilidis, G Sfakiotaki, J Souglakos et al. Bevacizumab plus oxaliplatin (LOHP), leukovorin (LV)/5-fluorouracil (5-FU) (FOLFOX4) as first line treatment of patients with metastatic colorectal cancer(MCC). **Ann Of Oncol Volume: 17 Pages: 70-71 Supplement: Suppl. 6 2006.**
32. A Voutsina, A Pallis, J Souglakos et al. Epidermal growth factor receptor mutations in Greek gefitinib-treated non-small-cell lung cancer (NSCLC) patients. **ANNALS OF ONCOLOGY Volume: 17 Pages: 42-42 Supplement: Suppl. 3 2006.**
33. J Souglakos, P Mendez, M Taron et al. BRCA1 mRNA expression levels are associated with clinical responses to front-line docetaxel/gemcitabine in patients with lung adenocarcinomas in an expanded multicentre phase II study. **EJC SUPPLEMENTS Volume: 5 Issue: 8 Pages: 33-33. 2007**
34. A Voutsina, A Kalykaki, Y Ampatziadis-Michailidis, J Souglakos et al. EGFR, K-RAS and HER2 mutations as predictive factors for gefitinib sensitivity in non-small cell lung cancer (NSCLC). **EJC SUPPLEMENTS Volume: 5 Issue: 8 Pages: 35-35. 2007**
35. Z. Saridaki, M. Tzardi, D. Papadatos-Patsos, E. Kampouraki, E. Zois, E. Stathopoulos, V. Georgoulas, D. Mavroudis, J Souglakos Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy. **EJC Supplements, Vol 7 No 2, September 2009, Page 91.**
36. M. Sfakianaki, C. Papadaki, D. Mavroudis, M. Trypaki, E. Lagoudaki, E. Stathopoulos, A. Xyrafas, E. Tsakalaki, V. Georgoulas, J Souglakos. Correlation of BRCA1, DAXX, TXN, TXR1 and TSP1 tumoral expression with resistance to docetaxel-based chemotherapy in patients with advanced/metastatic Non Small Cell Lung Cancer. **EJC Supplements, Vol 7 No 2, September 2009, Page 108.**
37. John Souglakos, George Pentheroudakis, Chara Papadaki, Andrés Cervantes, Dimitris Petrakis, Edith Roodriguez-Braun, Eletheria Tsikalaki, Eleni Lagoudaki, Vassilis Georgoulas, Dimitris Mavroudis, Nicholas Pavlidis Prognostic significance of gene expression profile in patients with Carcinomas of Unknown Primary (CaUP) **Ann Oncol Supplements 2010;6(6): 55-55 Abstr No 128P**
38. Ch. Papadaki, M. Sfakianaki, El. Lagoudaki, G. Giagkas, El Tsakalaki, M. Trypaki, S. Pontikakis, Asimina Koulouridi, V. Georgoulas, J Souglakos. PKM2 expression may predict chemosensitivity to cisplatin-based chemotherapy in metastatic non-small cell lung cancer (NSCLC) **Ann Oncol 2012: Abstr No 1308P**
39. Chara Papadaki, George Pentheroudakis, Andrés Cervantes, Eleni Lagoudaki. Dimitris Petrakis John Souglakos, Edith Roodriguez-Braun, Eleftheria Tsikalaki, Vassilis

- Georgoulas, Dimitris Mavroudis, Nicholas Pavlidis Prognostic and predictive significance of pharmacogenetic analysis in patients with Carcinomas of Unknown Primary (CaUP) **Ann Oncol 2012: Abstr No 1170P**
40. Z Saridaki, M Tzardi, M Sfakianaki, Ch. Papadaki, K Mpananis, El Tsakalaki, M. Trypaki, I Messaritakis, V Georgoulas, J Souglakos *BRAFV600E* mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, prognostic and predictive values Ann Oncol 2012: Abstr No 631
41. N. Karachaliou, C. Costa, A. Gimenez-Capitan, S. Viteri, A. Gasco, C. Camps, E. Carcereny, B. Massuti Sureda, J. Souglakos, R. Rosell High mRNA Expression Of LMO4, A BRCA1 Downregulator, Correlates With Better Prognosis In Erlotinib-Treated Non-Small-Cell Lung Cancer (Nslc) Patients (P) With Egfr Mutations **Ann Oncol 2012: Abstr No 1655**
42. Daniel Sargent, Ph.D.; James Paul, B.Sc.; Alberto Sobrero, M.D.; Thierry André, M.D.; Anthony F. Shields, M.D.; Takayuki Yoshino, M.D.; Ioannis Souglakos, M.D.; Timothy Iveson, M.D.; Roberto Labianca, M.D.; Julien Taieb, M.D., Ph.D.; Jeffrey A. Meyerhardt, M.D., MPH; Atsushi Ohtsu, M.D.; Axel Grothey, M.D. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: a prospective pooled analysis of > 11,500 patients from 6 Phase III trials of adjuvant therapy duration with FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) for stage III colon cancer. Ann Oncol 2014: Abstr No 718

IV. Other Congresses Proceedings (3 Citations)

1. Kakolyris S, Kourousis C, Cheras P, Vamvakas L, Kalbakis K, Vlata M, Schiza S, Souglakos J, Alissandrakis K, Kavalos S, Hatzidaki D, Androulakis N, Samonis G, Georgoulis V : First line treatment of advanced breast cancer with Vinorelbine Mitoxanthrone and Carboplatine A Preliminary Report. **6th International Congress on Anti-Cancer Treatment - Paris February 6th-9th 1996.**
2. Kourousis C, Kakolyris S, Cheras P, Androulakis N, Vamvakas L, Vlata M, Kalbakis K, Souglakos J, Alissandrakis K, Schiza S, Kavalos S, Hatzidaki D, Samonis G, Georgoulis V : A preliminary report of an active salvage chemotherapy combining Vinorelbine, Paclitaxel and CDDP in Anthracycline resistant advanced breast cancer. **6th International Congress on Anti-Cancer Treatment - Paris February 6th-9th 1996.**
3. Kourousis C, Androulakis N, Cheras P, Vamvakas L, Metaxaris G, Souglakos J, Vlastos F, Dimadi M, Vossos A, Aravosita P, Georgopoulou Th, Papandreou D, Hatzidaki D, Papadakis E, Georgoulis V : Monotherapy with Docetaxel in previously treated patients with advanced Non-Small Cell Lung Carcinoma **Lung Cancer November 9-13 1996**
4. Georgoulis, N. Androulakis, A. M. Dimopoulos, C. Kourousis, S. Kakolyris, E. Papadakis, F. Apostolopoulou, F. Papadimitriou, A. Vossos, M. Aggelidou, P. Heras, S. Tzannes, J. Souglakos and D. Hatzidaki: Treatment of non-small-cell lung cancer. Stages IIIB and IV with docetaxel and cisplatin. **IALT 1997 Abstr # 164. (Cited 1)**
5. Gianakakis T, Papadouris S, Ziras N, Kourousis C, Kakolyris S, Mavroudis D, Ziani D, Vakaloudi N, Papadakis E, Androulakis N, Souglakos J, Sara E, Hatzidaki D, Georgoulis V : Interim analysis of a Phase I/II study of Docetaxel and Carboplatin (CBP) as 1st line chemotherapy for advanced Non-Small Cell Lung Cancer (NSCLC). **8th International Congress on Anti-Cancer Treatment - Paris February 3th-6th 1998.**
6. Kourousis C, Androulakis N, Souglakos J, Kakolyris S, Kotsakis A, Dimopoulos A.M., Kalbakis K, Katsogridakis K, Prinianakis G, Samonis G, Georgoulis V : Acute Inflammatory Abdominal Events complicating Taxane-Based chemotherapy : A report of four Cases. **8th International Congress on Anti-Cancer Treatment - Paris February 3th-6th 1998.**
7. Kakolyris S, Kourousis C, Androulakis N, Souglakos J, Mavroudis D, Kalbakis K, Agelaki S, Kotsakis A, Prinianakis G, Vardakis N, Hatzidaki D, Georgoulis V : Phase I study of cis Platin and Irinotecan (CPT-11) in metastatic Non Small Cell Lung Cancer. **8th International Congress on Anti-Cancer Treatment - Paris February 3th-6th 1998.**
8. Androulakis N, Kourousis C, Kakolyris S, Sara E, Souglakos J, Kalbakis K, Agelaki S, Kalikaki T, Kois S, Vardakis N, Samonis G, Georgoulis V : Monotherapy with

Docetaxel and Granulocyte Colony-Stimulating Factor in Advanced Gastric Cancer. **B.U.ON. Ismir September 1998.**

9. D. Mavroudis, N. Malamos, Ch. Kouroussis, S. Agelaki, Th. Giannakakis, A. Alexopoulos, I. Stavrakakis, A. Potamianou, N. Ziras, G. Rigatos, Ch. Kosmas, J. Souglakos, N. Vardakis, E. Sarra, S. Papadouris, Ch. Georganta, V. Georgoulis : Salvage chemotherapy of metastatic breast cancer with docetaxel and gemcitabine : A multicenter phase II trial. **B.U.ON. Ismir September 1998.**
10. Alexopoulos, Ch. Kouroussis, N. Malamos, G. Rigatos, Th. Giannakakis, N. Androulakis, S. Kakolyris, D. Mavroudis, E. Stavrinidis, G. Panagos, S. Agelaki, Ch. Kosmas, J. Souglakos, N. Vardakis, F. Apostolaki, E. Sarra, V. Georgoulis : Treatment of metastatic breast cancer with intensified combination of docetaxel and mitoxantrone : A multicenter phase II trial. . **B.U.ON. Ismir September 1998.**
11. Ch. Kouroussis, D. Mavroudis, S. Kakolyris, N. Androulakis, S. Agelaki, K. Kalbakis, E. Sarra, J. Souglakos, T. Kalikaki, G. Perisinaki, S. Kois, V. Georgoulis : Phase I study of weekly paclitaxel in advanced solid tumors : A preliminary report. **B.U.ON. Ismir September 1998**
12. S. Kakolyris, Ch. Kouroussis, J. Souglakos, N. Androulakis, D. Mavroudis, K. Kalbakis, A. Kotsakis, E. Sarra, S. Agelaki, G. Samonis, V. Georgoulis : Phase I study of Irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC). **B.U.ON. Ismir September 1998**
13. Androulakis N, Kourousis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou Ch, Geroyanni A, Georgopoulou Th, Dimopoulou I, Souglakos J, Tzianni V, Apostolaki F, Kotsakis A, Vardakis N, Kalikaki T, Hatzidaki D, Samonis G, Georgoulis V : Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel- based chemotherapy: a multicenter phase II study. **5th Central European Lung Cancer Conference. Prague, September 13 - 16, 1998.**
14. Th. Giannakakis, D. Mavroudis, S. Papadouris, Ch. Kouroussis, N. Ziras, S. Kakolyris, K. Kalbakis, S. Agelaki, D. Zianni, V. Zianni, E. Lidaki, N. Vakaloudi, E. Papadakis, N. Androulakis, J. Souglakos, S. Kois, E. Sarra, D. Hatzidaki, V. Georgoulis : Phase I/II trial of docetaxel (D) and carboplatin (CBDCA) ad first-line chemotherapy in advanced non-small cell lung cancer (NSCLC). **5th Central European Lung Cancer Conference. Prague, September 13 - 16, 1998.**
15. S. Kakolyris, Ch. Kouroussis, J. Souglakos, N. Androulakis, D. Mavroudis, K. Kalbakis, A. Kotsakis, E. Sarra, S. Agelaki, G. Prinianakis, N. Vardakis, G. Samonis, V. Georgoulis : Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC). **5th Central European Lung Cancer Conference. Prague, September 13 - 16, 1998**
16. Kourousis C, Mavroudis D, Gianakakis T, Ziras N, Athanasiadis S, Kakolyris S, Androulakis N, Kalbakis K, Agelaki S, Souglakos J, Sara E, Vardakis N, Georgoulis V. Greek Cooperative Group for the Study of Colorectal Cancer.: Biweekly oxaliplatin and high dose Leukovorin and 5 - Fluorouracil (5-FU) 48-hour continuous infusion in

pretreated patients with advanced colorectal cancer (CRC) **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**

17. Kourousis C, Androulakis N, Mavroudis D, Kakolyris S, Agelaki S, Sara E, Souglakos J, Kalikaki T, Perisinaki G, Mandalaki K, Georgoulis V. : Phase I study of weekly Docetaxel in advanced solid tumors. **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**
18. Mavroudis D, Malamos N, Giannakakis Th, Alexopoulos A, Potamianou A, Rigatos G, Kosmas, Sarra E, N, Papaduris, Malliotakis P, Souglakos J, Georgoulis V : A Phase II trial of Docetaxel and Gemcitabine as second line treatment in metastatic Breast Cancer. **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**
19. Alexopoulos A, Malamos N, Gianakakis T, Mavroudis D, Panagos S, Agelaki S, Sara E, Cosmas Ch, Souglakos J, Vardakis N, Apostolaki F, Apostolaki F, Georgoulis V : A phase I/II study of Docitaxel (D) and Mitoxanthrone (M) in metastatic Breast Cancer. **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**
20. Panagos G, Mavroudis D, Potamianou A, Malamos N, Kosmas Ch, Kourousis Ch, Kakolyris S, Xydakis E, Souglakos J, Sarra E, Giannakakis Th, Georgoulis V : A Phase II trial of Docetaxel and Gemcitabine as second line treatment in metastatic Breast Cancer. **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**
21. Ch. Kouroussis, D. Mavroudis, Th. Giannakakis, N. Ziras, A. Athanasiadis, S. Kakolyris, N. Androulakis, K. Kalbakis, S. Agelaki, J. Souglakos, E. Sarra, N. Vardakis : Biweekly Oxaliplatin (L-OHP) with high-dose Leucovorin (LV) and 5-Fluorouracil (5-FU) 48-hour continuous infusion in pretreated patients with advanced colorectal cancer (CRC). . **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**
22. Ch. Kouroussis, N. Androulakis, D. Mavroudis, S. Kakolyris, S. Agelaki, E. Sarra, J. Souglakos, T. Kalikaki, G. Perisinaki, K. Mandalaki, V. Georgoulis : Phase I study of weekly docetaxel in advanced solid tumors. **9th International Congress on Anti-Cancer Treatment - Paris February 2nd-5th 1999.**
23. S Kakolyris, Ch. Kouroussis, D Mavroudis, N Androulakis, S. Agelaki, K Kalbakis, E Kremos, E Sarra, J. Souglakos, N Vardakis, V Georgoulis : Second-line treatment with cisplatin and irinotecan (CPT-11) in patients with advanced non-small cell lung cancer (NSCLC). **International Congress on Anti-Cancer Treatment - Paris January 31th-February 3th 2000.**
24. Th. Giannakakis, P Panopoulos, D. Mavroudis, S. Agelaki, N. Androulakis, E Kazakou, J. Souglakos, I Mixaki, N. Ziras, A. Athanasiadis, G Samonis, V Georgoulis : Biweekly Oxaliplatin (L-OHP) with high-dose Leucovorin (LV) and 5-Fluorouracil (5-FU) 48-hour continuous infusion in irinotecan pretreated patients with advanced

colorectal cancer (CRC). **International Congress on Anti-Cancer Treatment - Paris January 31th-February 3th 2000.**

25. Ch. Kouroussis, S. Kakolyris, D. Mavroudis, K Kalbakis, S. Agelaki, E Sarra, J. Souglakos, N. Vardakis, P Malliotakis, V Georgoulas : Front line treatment of metastatic breast cancer (MBC) and non-small lung cancer (NSCLC) with Docetaxel (D) and Oxaliplatin (L-OHP) : a dose-escalation study. **International Congress on Anti-Cancer Treatment - Paris January 31th-February 3th 2000.**
26. S. Agelaki, C Kouroussis, D. Mavroudis, K Kalbakis, J. Souglakos, D Reppa, I Isbarah, I Mixaki, V Georgoulas : A phase I study of Docetaxel (D) and Oxaliplatin (L-OHP) as front line treatment in metastatic breast cancer (MBC) and non-small lung cancer (NSCLC). **9thWorld conference on Lung Cancer Tokyo 11-15 Sep 2000. (Citations: 1)**
27. S. Kakolyris, C Kouroussis, D Mavroudis, J. Souglakos, K Kalbakis, S. Agelaki, N Vardakis, L Vamvakas, D Reppa, V Georgoulas : A phase I study of irinotecan (CPT-11) and Gemcitabine combination as salvage treatment in patients with advanced non-small cell lung cancer. **9thWorld conference on Lung Cancer Tokyo 11-15 Sep 2000.**
28. C Kouroussis, S Kakolyris, G Staphopoulos, D Mavroudis, K Kalbakis, J. Souglakos, L Vamvakas, I Mixaki, G Samonis, V Georgoulas : Phase I study of weekly Docetaxel (D) and Gemcitabine (G) in advanced non-small cell lung cancer. **9thWorld conference on Lung Cancer Tokyo 11-15 Sep 2000.**
29. Th. Giannakakis, S. Kakolyris, P Papadouris, I Theodoropoulos, K Kalbakis, N. Androulakis, J. Souglakos, S. Agelaki, P Malliotakis, V Georgoulas : Phase II study of Docetaxel (TXT) and Carboplatin (CBDCA) combination advanced non-small cell lung cancer (NSCLC). **9thWorld conference on Lung Cancer Tokyo 11-15 Sep 2000.**
30. S. Kakolyris, N. Androulakis, S. Agelaki, D. Mavroudis, J. Souglakos, N. Vardakis, D. Reppa, G. Samonis, V. Georgoulas : Salvage treatment of taxanes refractory advanced non-small cell lung cancer (NSCLC) with cisplatin plus irinotecan (CPT-11) combination. **9thWorld conference on Lung Cancer Tokyo 11-15 Sep 2000.**
31. S. Kakolyris, C Kouroussis, J. Souglakos, K Kalbakis, D. Mavroudis, E. Adamtziki, N. Xenidis, L. Vamvakas, V. Georgoulas : A phase I clinical trial of topotecan given biweekly in patients with refractory solid tumors. **11th International Congress on Anti-Cancer Treatment Paris 2001.**
32. J. Souglakos, C Kouroussis, D. Mavroudis, S. Kakolyris, K Kalbakis, S. Agelaki, N. Vardakis, K. Mallas, L. Vamvakas, C. Malliotakis, V. Georgoulas : Weekly irinotecan and Leucovorin and 5-Fluorouracil (AIO schedule) in pretreated patients with advanced colorectal cancer: Preliminary results. **11th International Congress on Anti-Cancer Treatment Paris 2001.**

33. C Kouroussis, S Kakolyris, D Mavroudis, K Kalbakis, G Staphopoulos, J. Souglakos, L Vamvakas, N Xenidis, G Samonis, V Georgoulas : A phase I study of weekly docetaxel (D) and gemcitabine (G) in advanced non-small cell lung cancer. **11th International Congress on Anti-Cancer Treatment Paris 2001.**
34. S. Kakolyris, Ch. Kouroussis, D. Mavroudis, J. Souglakos, K. Kalbakis, S. Agelaki, N. Vardakis, L. Vamvakas, D. Reppa, V. Georgoulas. A Phase I Study of Irinotecan (CPT-11) and Gemcitabine Combination as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer. **4th International Congress on Lung Cancer, Halkidiki-Greece, April 2001.**
35. Ch. Kouroussis, S. Kakolyris, D. Mavroudis, K. Kalbakis, J. Souglakos, L. Vamvakas, K. Malas, V. Bozionelou, N. Androulakis, H. Adamtziki, N. Xenidis, V. Georgoulas. A Phase I Study of Weekly Docetaxel (D) and Gemcitabine (G) in Advanced Non-Small Cell Lung Cancer. **4th International Congress on Lung Cancer, Halkidiki-Greece, April 2001.**
36. S. Agelaki, Ch. Kouroussis, D. Mavroudis, K. Kalbakis, J. Souglakos, D. Reppa, I. Isbarach, I. Mixaki, V. Georgoulas. A Phase I Study of Docetaxel (D) and Oxaliplatin (L-OHP) as Front-Line Treatment in Metastatic Breast Cancer (MBC) and Non-Small Cell Lung Cancer. **4th International Congress on Lung Cancer, Halkidiki-Greece, April 2001.**
37. T. Giannakakis, S. Kakolyris, E. Michailakis, S. Papadouris, K. Malas, K. Kalbakis, N. Androulakis, J. Souglakos, S. Agelaki, L. Vamvakas, N. Vardakis, A. Pallis, V. Georgoulas. Final Results of a Phase II Study of Docetaxel (TXT) and Carboplatin (CBDCA) Combination in Advanced Non-Small Cell Lung Cancer (NSCLC). An Ongoing Study. **4th International Congress on Lung Cancer, Halkidiki-Greece, April 2001.**
38. J. Souglakos, I.G. Vlachonikolis. Dietary Factors and Risk of Colorectal Cancer: Results from a Case-Control Study in Crete. Greece. **3rd International Conference Dublin, Ireland, June 2001.**
39. J. Souglakos, S. Kakolyris, N. Androulakis, Ch. Kouroussis, K. Kalbakis, S. Agelaki, N. Vardakis, V. Bozionelou, A. Pallis, V. Georgoulas. A Phase I Study with Oxaliplatin (L-OHP) plus Leukovorin (LV)/5-Fluorouracil (5-FU) in a Weekly Schedule (AIO) in Patient with Advanced Solid Tumors. Preliminary Results. **3rd International Conference Dublin, Ireland, June 2001.**
40. Phase I study of Capecitabine combination with radiotherapy as adjuvant treatment for operable rectal cancer: Finally Results. **J. Souglakos**, N. Vardakis, N. Androulakis, K. Kalbakis, S. Agelaki, N. Xenidis, P Kafarakis, A. Pallis, V. Georgoulas. Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece **4^{ra} International Conference Barcelona, June 2002.**
41. Phase I study of biweekly oxaliplatin (LOHP) in combination with weekly administration of leukovorin (LV) and continuous 5-fluoruracil (5-FU) infusion in

- patients with advanced solid malignancies. J. Souglakos, N. Vardakis, K. Kalbakis, N. Androulakis, Ch. Kouroussis, S. Kakolyris, A Pallis, P Kafarakis, N Xenidis, V. Georgoulas. Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece. **4^{ra} International Conference Barcelona, June 2002.**
42. Different Schedules of Edrocolomab administration in colorectal cancer patients with CEA-mRNA-positive cells in the peripheral blood. N Vardakis, M Peraki, D Mavroudis, J Souglakos, N Androulakis, V Georgoulas. . **4^{ra} International Conference Barcelona, June 2002.**
43. Oxaliplatin (L-OHP) combined with Irinotecan (CPT-11), Leucovorin (LV) and 5-Fluorouracil(5-FU) (FOLFOXIRI) compared with CPT-11, LV and 5-FU (FOLFIRI) as first-line treatment for metastatic colorectal cancer: Preliminary safety and efficacy results of a multicenter randomized trial. N. Androulakis, N. Vardakis, J. Souglakos, K Kalbakis, N Pallis, A. Athanasiadis, P. Ginopoulos, Th. Giannakakis, K. Syrigos, V. Georgoulas. For the Greek Cooperative Group for Colorectal Cancer, Greece. **4^{ra} International Conference Barcelona, June 2002.**
44. J. Souglakos, N. Vardakis, A Pallis, N. Androulakis, Ch. Kouroussis, S. Kakolyris, Z Saridaki, N Tzenakis, N Xenidis, V. Georgoulas. Phase I study of biweekly oxaliplatin (LOHP) alternating with irinotecan (CPT-11) in combination with weekly administration of leukovorin (LV) and continuous 5-fluoruracil (5-FU) infusion in patients with advanced solid malignancies. **5th International Conference Barcelona, June 2003.**
45. J. Souglakos, N. Androulakis, S. Kakolyris, G Milaki, N Xenidis, N. Vardakis, A Pallis, G Garidas, G Roditakis, V. Georgoulas. Phase I study of biweekly oxaliplatin (LOHP) with irinotecan (CPT-11) in combination with Xeloda in patients with advanced solid malignancies. **5th International Conference Barcelona, June 2003. (Citations 1)**
46. J. Souglakos, A Pallis, N Androulakis, N Xenidis, N Vardakis, Ch Kourousis, S Kakolyris, S Agelaki, G Milaki, V Georgoulas. Combination Of Irinotecan (Cpt-11) Plus Bolus Plus Continuous Infusion 5-Fluorouracil (5-Fu) And Leucovorin (Lv) (Folfiri) As First Line Treatment For Elderly Patients With Metastatic Colorectal Cancer (Mcc): A Phase Ii Tria. **5th International Conference Barcelona, June 2003.**
47. Z Saridaki, J. Souglakos, M Tzardi, M Peraki, D Mavroudis, V Georgoulas. Microsatellite Instability (Msi) Status In 31 Colorectal Cancer Patients Treated With A Triplet Combination With Irinotecan (Cpt-11), Oxaliplatin (L-Ohp) Plus Bolus And Infusional 5fu/Leucovorin (Degramont Regimen)-Folfoxiri- As First Line Treatment: Correlation Of Allelic Imbalance With Clinical Parameters And Treatment Outcomes. **5th International Conference Barcelona, June 2003.**
48. J. Souglakos, N Androulakis, D Tsetis, Th Kokkinakis, D Mavroudis, Ch Kourousis, S Agelaki, K Kalbakis, Z Saridaki, V Georgoulas PRELIMINARY RESULTS OF A PILOT PHASE II OF CRONOMODULATED FOLFOX AS SALVAGE TREATMENT FRO PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)**World Congress on Gastrointestinal Cancer Barcelona June 2004 (P87)**

49. N Vardakis, J Souglakos, N. Androulakis, L Vamvakas, Ch. Kouroussis, N Katsougris, S Giassas, N Keteposidis, D Mavroudis, V. Georgoulas Phase I study of biweekly oxaliplatin (LOHP) with capecitabine (Xeloda) in combination with ZD1839 (Iressa) in patients with pretreated advanced colorectal cancer **World Congress on Gastrointestinal Cancer Barcelona June 2004 (P88)**
50. J Souglakos, Z Saridaki, A Pallis, L Vamvakas, K Kalbakis, D Mavroudis, G Milaki, A Kotsakis, M Ignatiadis, V Georgoulas COMBINATION OF IRINOTECAN (CPT-11) AND GEFINITIB (ZD1839) FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC) REFRACTORY TO IRINOTECAN-BASED 1ST LINE CHEMOTHERAPY: A PILOT PHASE II STUDY **World Congress on Gastrointestinal Cancer Barcelona June 2004 (P89)**
51. J Souglakos, A. Pallis, S. Kakolyris, D. Mavroudis, N. Androulakis, Ch. Kouroussis, S. Agelaki, N. Xenidis, G. Milaki, V. Georgoulas. Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. **5th BUON Belgrade October 2004.**
52. J Souglakos, N Androulakis, A Kalykaki, Z Saridaki, N Vardakis, K Kalbakis, S Agelaki, N Kentepozidis, S Giassas, D Mavroudis, V Georgoulas Cetuximab plus Xelox as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including Oxaliplatin (LOHP), irinotecan (CPT-11), and 5-fluorouracil (5-FU) or Capecitabine (CAP) **TAT 2005 (P508).**
53. J Souglakos TREATMENT WITH DOCETAXEL METHYL-PREDNIZOLONE OF A PATIENT WITH HORMONE INDEPENDENT PROSTATE CANCER **4th MASTERCLASS IN ONCOLOGY Limassol March 2005.**
54. D Papadatos-Pastos, M Tzardi, Z Saridaki, J Souglakos, N Zois, M Peraki, D Mavroudis, V Georgoulas Correlation Of Microsatellite Instability (Msi) Status With Clinical Parameters And Treatment Outcomes For 58 Patients With Metastatic Colorectal Cancer (Mcc) Treated With A Triplet Combination With Irinotecan (Cpt-11), Oxaliplatin (L-Ohp) Plus Bolus And Infusional 5fu/Leucovorin (DeGramont regimen)-FOLFOXIRI **World Congress on Gastrointestinal Cancer Barcelona June 2006**
55. C. Emmanouilides, G. Sfakiotaki, J Souglakos, D. Mavroudis, N. Androulakis, A. Kalykaki, A. Kotsakis, K. Kalbakis, E. Diamandidou, N. Touroutoglou, V. Georgoulas Bevacizumab with oxaliplatin leukovorin 5-fluorouracil (FOLFOX) as first line treatment of metastatic colorectal cancer **World Congress on Gastrointestinal Cancer Barcelona June 2006.**
56. L. Vamvakas, N. Androulakis, K. Syrigos, A. Polyzos, N. Ziras, A. Athanasiadis, S. Kakolyris, S. Tsousis, Ch. Kouroussis, A. Kalykaki, G. Samonis, D. Mavroudis, V. Georgoulas, J. Souglakos. Folfoxiri (Folinic Acid, 5-Fluorouracil, Oxaliplatin And Irinotecan) Versus Folfiri (Folinic Acid, 5-Fluorouracil And Irinotecan) As First Line Treatment In Metastatic Colorectal Cancer (Mcc): A Subgroup Analysis For Elderly Patients Of A Multicenter Randomized Phase Iii Trial From The Hellenic Oncology

Research Group (HORG). **CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY Volume: 63 Pages: S49-S49 Supplement: Suppl. 1**

57. L Vamvakas, A Karabeazis, A Ardavanis, J Souglakos, K Kalbakis, N Vardakis, Ch Kourousis, N Malamos, I Varthalitis, D Mavroudis. Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)**CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY Volume: 64 Pages: S49-S49 Supplement: Suppl. 1.**
58. I Boukovinas, P Mendez, D Mavroudis, A Koutsopoulos, M Trypaki, C Papadaki, A Voutsina, M Taron, V Georgoulas, R Rosell, J Souglakos. Tumoral BRCA1 mRNA expression levels are associated with clinical responses to front-line docetaxel/gemcitabine chemotherapy in patients with lung adenocarcinomas. **EORTC-NCI-AACR Congress 2007 Abstr # 15.**
59. John Souglakos How close are we to customizing chemotherapy in early NSCLC **Journal of Thoracic Oncology 2010;5(5)s1:s23-s23**
60. Papadaki, Ch, Sfakianaki, M., Lagoudaki, E., Ioannidis, G, Tsakalaki, E., Trypaki, M., Giagkas, G., Pontikakis, S, Stathopoulos, E., Mavroudis, D, Georgoulas, V., Souglakos, J PKM2 As A Biomarker For Chemosensitivity To Cisplatin-Based Chemotherapy In Metastatic/Advanced Non-Small Cell Lung Cancer (NSCLC). **Journal Of Thoracic Oncology 2011; Vol 6, Issue: 6, Pages: S998-S998, Suppl**
61. Ioannidis, G Papadaki, Ch Sfakianaki, M Lagoudaki, E., Tsakalaki, E, Trypaki, M Hatzidaki, D Stathopoulos, E Mavroudis, D Georgoulas, V Souglakos, J. Predictive and prognostic role of gemcitabine-related genes in advanced non-small cell lung cancer. **Journal Of Thoracic Oncology 2011; Vol 6, Issue: 6, Pages: S1086-S1087, Suppl**
62. Ippokratis Messaritakis, Kyriakos Mpananis, Nikolaos Vardakis, Chara Papadaki, Maria Sfakianaki, Zacharenia Saridaki, Christos Fokoloros, Demitris Mavroudis, Vassilis Georgoulas, John Souglakos Prognostic significance of *CEACAM5* mRNA-positive cells detection in the peripheral blood of patients with metastatic colorectal cancer (mCRC). **Advances in Circulating Tumor Cells, Athens 2012.**
63. Ippokratis Messaritakis, Dimitris Stoltidis, Kyriakos Mpananis, Chara Papadaki, Maria Sfakianaki, Eleni Lagoudaki, Asimina Koulouridi, Christos Fokoloros, Dimitris Mavroudis, Vassilis Georgoulas, John Souglakos Detection of CD56- and/or TTF1-positive Circulating Tumor Cells (CTCs) in the peripheral blood of patients with Small Cell Lung Cancer (SCLC) **Advances in Circulating Tumor Cells, Athens 2012.**
64. Demetris Stoltidis, Ippokratis Messaritakis, Sofia Agelaki, Chara Papadaki, Maria Sfakianaki, Stella Apostolaki, Christos Fokoloros, Thanos Kotsakis, Demitris Mavroudis, Vassilis Georgoulas, John Souglakos Detection of Circulating Tumor Cells (CTCs) in the peripheral blood of patients with refractory or resistant Small Cell Lung

Cancer (SCLC) treated with Pazopanib as surrogate marker for treatment outcome. **Advances in Circulating Tumor Cells, Athens 2012.**

- L. Vamvakas, A. Karampeazis, I. Boukovinas, S. Kakolyris, A. Polyzos, G. Nintos, T. Bilidas, M. Stratigos, V. Georgoulis, J. Souglakos and Hellenic Oncology Research Group (HORG) A RETROSPECTIVE ANALYSIS REGARDING THE PARAMETERS, WHICH INFLUENCE THE ADMINISTRATION OF ADJUVANT CHEMOTHERAPY IN FOR ELDERLY PATIENTS (> 70 YEARS) WITH STAGE II OR III COLON CANCER IN THE DAILY CLINICAL PRACTICE. SIOG 2013.
66. Ippokratis Messaritakis, Dimitris Stoltidis, Stella Apostolaki, Chara Papadaki, Maria Sfakianaki, Eleni Lagoudaki, Eleni Politaki, Dimitris Mavroudis, Vassilis Georgoulis, John Souglakos. Detection of Circulating Tumor Cells (CTCs) in the peripheral blood of patients with untreated Small Cell Lung Cancer (SCLC) using both the CellSearch platform and staining with TTF1 and CD56: correlation with clinico-pathological features. International Symposium on Minimal Residual Cancer, Paris, 2013.
67. Phase I Trial of Panitumumab in Combination with Cisplatin, Fluourouracil and Docetaxel (mDCF) in Advanced/Metastatic Gastric Cancer I Boukovinas, N Kentepozidis, L Vamvakas, A Karampeazis, I Varthalitis, Ch Emmanouilides, K Kalbakis, A Athanasiadis, V Georgoulis, J Souglakos Hellenic Oncology Research Group. WGIC, Barcelona 2013.
68. Phase II trial of mFOLIRI plus Bevacizumab as 1st line treatment in elderly patients with metastatic colorectal cancer L Vamvaks, A Karampeazis, N Kentepozidis, A Christopoulou, K Kalbakis, F Koinis, El Papadimitraki, D Hatzidaki, V Georgoulis, J Souglakos. WGIC, Barcelona 2013.
69. PKM2 expression could predict resistance to oxaliplatin combination chemotherapy in patients with stage II/III or metastatic colorectal cancer. Z. Saridaki, Ch. Papadaki, M. Tzardi, M. Sfakianaki, G. Sfakiotaki, G. Giagas, Ip. Messaritakis, El. Tsakalaki, M. Trypaki, D. Mavroudis, V. Georgoulis, J. Souglakos. WGIC, Barcelona 2013.
70. G. Ioannidis¹, Ch. Papadaki, El. Lagoudaki, El. Tsakalaki, M. Trypaki, E. Stathopoulos, D. Mavroudis, V. Georgoulis, J. Souglakos Gemcitabine (Gem) sensitivity-related gene mRNA expression and clinical outcome in advanced non-small cell lung cancer (aNSCLC). 4th European Lung Cancer Conference (ELCC) 2014. J Thorax Oncol; Volume: 9 Issue: 4 Supplement: 1 Pages: S20-S20 Meeting Abstract: 42P
71. Michelakis, D; Messaritakis, I; Lasithiotakis, K; Ioannou, H; Souglakos, I; Stamatiou, D; Zoras, O PROGNOSTIC VALUE OF PERIOPERATIVE ASSESSMENT OF CIRCULATING MELANOMA CELLS IN HYPERTHERMIC-ISOLATED LIMB PERFUSION: INTERIM RESULTS Michelakis, D; Messaritakis, I; Lasithiotakis, K; Ioannou, H; Souglakos, I;

Stamatiou, D; Zoras, O ANTICANCER RESEARCH Meeting Abstract: 421 Volume: 34 Issue: 10 Pages: 6059-6060 Published: OCT 2014

72. Michelakis, D; Messaritakis, I; Lasithiotakis, K; Ioannou, C; Souglakos, I; Stamatiou, D; Koronidou, K; de Bree, E; Zoras, O Hyperthermie isolated limb perfusion for locally recurrent melanoma of the limbs: Potential role of circulating tumor cells in disease outcome INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE Meeting Abstract: 469 Volume: 36 Pages: S97-S97 Supplement: 1 Published: 2015
73. DETECTION OF THE COMPLEXES OF PYRUVATE KINASE (PKM2) IN NON-SMALL CELL LUNG CANCER CELL LINES EuPA 2016 - X Annual Congress of the European Proteomics Association. (Abs #: 0096).
74. John Souglakos, Zacharenia Saridaki, Nikolaos Gouvas, Alexandra Voutsina, Maria Tzardi, Aristeia Kalikaki, Maria Sfakianaki, Athanasios Athanasiadis, Evangelos Xynos, Ioannis Boukovinas Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG). WGIC, Barcelona 2016. (Abs #: 356).

62 Abstracts in Greek Medical Congresses

Recommendation Letters

- Demetris Mavroudis Professor of Medical Oncology, Medical School, University of Crete (mavrudis@med.uoc.gr)
- Evi Lianidou Professor of Clinical Chemistry, Department of Chemistry, University of Athens (lianidou@chem.uoa.gr)
- Rafael Rosell Professor of Medical Oncology, University of Barcelona and Institute Catalan de Oncologie, Spain (rosell@ico.scs.es, rosell@iconcologia.net)
- Ramesh Shivdasani Associate Professor of Clinical Oncology, Dana-Farber Cancer Institute, Harvard University Medical School (Ramesh_Shivdasani@dfci.harvard.edu)